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ABSTRACT
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Platinum anticancer compounds with cis geometry, similar to cisplatin, have been explored
to circumvent the cisplatin resistance; however, they were not considered broadly active in
cisplatin cells due to exhibiting similar or same cell death mechanism as cisplatin. Platinum
compounds with trans geometry were less studied due to transplatin being clinically inactive; but
with few structural modifications, they resulted in unaffected cytotoxic activities in cisplatin
resistant cells with structural modification by exhibiting different modes of DNA binding. This
research focused on further exploring and establishing structure-activity relationship of two
promising non-classical series of platinum compounds with trans-geometry: trans-platinum planar
amine (TPA) compounds and noncovalently binding polynuclear platinum compounds (PPC-NC).
During this research, further optimizations of the reactivity of TPA compounds were
accomplished by modifying the leaving carboxylate groups. The effects of modified reactivity
were probed by a systematic combination of chemical and biophysical assays, followed by

xxi

evaluating their biological effects in cells. To establish the structural-activity relationship of PPCNCs, Mono-, Di-, Tri-, and Tetraplatin NC with charge of 4+, 6+, 8+, and 10+ were synthesized
and evaluated by utilizing biophysical and biological assays. Lastly, a new class of polynuclear
platinum compounds, Hybrid-PPCs, were synthesized and evaluated to overcome the
pharmacokinetic problems of BBR3464, phase II clinical trial anticancer drug developed
previously in our laboratory.
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Chapter 1

Introduction

CHAPTER 1.

INTRODUCTION

1.1 Cancer
Cancer is a group of diseases characterized by the uncontrolled growth and spread of
abnormal cells with a specific capacity to invade and destroy tissues and organs almost anywhere
in the body. Although the causes of cancer are not apparent, 90-95% of cancers are thought to be
caused by environmental factors: tobacco, diet and obesity, infections, radiation, stress, lack of
physical activity, and environmental pollutants (1). Approximately 5–10% of cancers are thought
to be caused due to genetic defects inherited from a person's parents (1). While the majority of the
cancers are preventable, continuous research efforts should be made to cure cancer since it is the
second most common cause of death in the United States, accounting for nearly 1 of every 4 deaths
(2).

Figure 1.1. The role of genes and environment in the development of cancer. A. The percentage
contribution of genetic and environmental factors to cancer. B. Family risk ratios for selected cancers. C.
Percentage contribution of each environmental factor From ref. (1).
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1.2 Treatments
Current treatment of cancer includes surgery, chemotherapy, radiation therapy, hormonal
therapy, targeted therapy, and palliative care. Treatments used depend upon the type, location, and
grade of the cancer as well as the person’s health and desires (3). Improvements in curability and
survivability are dependent on advances in early detection, surgery, radiotherapy, and
chemotherapy; but once widespread metastatic disease has become established, chemotherapy is
a central component of management (4). Treatments like radiation and surgery are considered as
local treatments since they act only in one area of the body. Chemotherapy differs from surgery or
radiation in that it is almost always used as a systemic treatment.
The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards with
antifolate drugs (5). Since then, many categories of chemotherapy drugs have been developed as
a single agent or combination therapy: alkylating agents, antimetabolites, anti-tumor antibiotics,
topoisomerase inhibitors, mitotic inhibitors, and corticosteroids (3). Despite significant advances
in chemotherapy, most of the cancer drugs have shown to induce toxic side effects and to develop
drug resistances (6).

1.3 Platinum-Based Chemotherapeutics
Cisplatin (cis-diamminedichloroplatinum(II)) was first described in 1845 and its antitumor
properties were accidently found by Rosenberg in 1965 (7,8). Since then platinum based antitumor
agents have been commonly used for the treatment of a wide range of solid tumors. Structurally,
cisplatin or cis-[Pt(NH3)2Cl2], consists of two inert ammine ligands and two labile chloride ligands
in cis conformation as shown in Figure 1.2. Platinum (II), exhibiting square planar geometry, tends
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to have a high affinity for nitrogen and sulfur molecules found commonly in proteins and
nucleobases in DNA

Figure 1.2. FDA approved platinum-based anticancer agents

The U.S. Food and Drug Administration (FDA) has approved three platinum based
antitumor agents, cisplatin and its derivatives, carboplatin and oxaliplatin, as single agents or as
part of combinatorial chemotherapy. Despite the clinical success of cisplatin and its derivatives,
dose-limiting toxic side effects and inherent and acquired resistance against approved platinum
compounds prompted the development of a new generation of antitumor agents (9,10,11).

1.4 Mechanism of Action of Cisplatin
Following administration of cisplatin into the bloodstream of a patient, replacement of its
chlorides by aquation is limited due to high chloride concentration in the blood plasma (~100 mM).
Once it enters the cell through passive diffusion or by active transporter (e.g. copper transporter
Ctr1) (12,13), it is more vulnerable to aquation due to much lower chloride concentration (~4 mM)
than the plasma (14). In cells, the drugs are likely to undergo hydrolysis to form positively charged
mono- and di-aquated active species by replacement of the chloride leaving group, resulting in
subsequent interactions with cellular nucleophiles (Figure 1.3) (15).
4

Figure 1.3. Mechanism of action of cisplatin

The ultimate target for cisplatin inside the cell is DNA and the active (aquated) species of
cisplatin can readily react with preferentially G7 on DNA bases guanine and adenine (16,17).
Initially, mono-functional adducts are formed, but most of them react further to form bi-functional
intra- and inter-strand cross-links, which induce structural distortions on DNA (Figure 1.4) (11,18).
Most adducts occur in the same DNA strand and involve adjacent bases, namely GpG 1,2
intrastrand (60-65% of all adducts) and ApG 1,2 intrastrand cross-links (20-25%) (19,20). These
cross-links bend DNA helix by 34° towards its major groove and unwind it by 13° (21); these
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structural distortions can impede cellular processes such as replication and transcription, ultimately
leading to apoptosis (22).

Figure 1.4. Formation of cisplatin adducts. From ref (23).

1.5 Cisplatin Resistance
The occurrence of resistance is a common drawback in cancer chemotherapy, and cisplatin
is no exception. Tumors are sensitive to cisplatin treatment predominantly; however, most of the
sensitive tumors develop resistance after the initial treatment (24,25). Resistance to cisplatin is
generally multifactorial and the principal mechanisms responsible for inherent and acquired
resistance are inactivation by sulfur containing molecules, reduced cellular accumulation due to
change of the uptake/efflux profile, and increased recognition and repair of cisplatin-DNA adducts
(11,26,27).
Although DNA is the core target for the vast majority of platinum anti-cancer compounds,
the critical step in measuring the clinical effectiveness of these drugs is to understand and measure
the metabolic interactions that may occur while traveling to the desired site of action. Platinum in
vivo, following aquation, acts as soft Lewis acids, and form stable complexes with S or N donors
found in proteins (28). Reaction with human serum albumin (HSA), a single chain protein
6

containing 17 disulfide bridges and one free thiol at Cys-34, is thought to be the main route for
inactivation in human blood plasma (29). Another known biomolecule responsible for cisplatin
inactivation is glutathione (GSH), an abundant thiol-containing tripeptide, which is present in a
concentration of 1~10 mM intracellularly (30). Clinical and preclinical studies of cellular systems
with elevated levels of HSA and GSH are significantly more resistant to cisplatin (31). From these
findings, therapeutic efficacy of platinum compound can be reflected as a balance between
metabolic inactivating interactions and biological consequence of DNA toxicity.

Figure 1.5.Structure of sulfur nucleophiles: Cysteine, methionine, and glutathone.

Widely used second generation platinum-based anticancer drugs, carboplatin and
oxaliplatin, were developed to address the pharmacokinetic problems of cisplatin by reducing the
reactivity of the drug. This was accomplished by replacing reactive chloride with a more stable bidentate carboxylate leaving group (32). This approach successfully minimized the interaction with
sulfur containing molecules, where this interaction is known to be responsible for a variety of
biological effects including drug inactivation, development of resistance, and toxic side effects
7

(33). Although utilizing more stable carboxylates resulted in enhanced stability to sulfur
nucleophiles, they are not considered broadly active in cisplatin-resistant cancers since they form
similar Pt-DNA adducts at the same sites on DNA as cisplatin (34,35,36,37,38).

Figure 1.6. Resistance to cisplatin and carboplatin mediated after DNA binding. From ref (10).

Formation and persistence of DNA adducts of cisplatin and its derivatives are crucial in
inducing apoptosis. Therefore, an increased rate of Pt-DNA adduct repair or removal of these
adducts will attenuate the apoptotic process, which has been associated with cisplatin resistance
(39,40,41,42). At present, several mechanisms of tolerance and removal of cisplatin-DNA adducts
are identified and shown in Figure 1.6. These cisplatin resistant mechanisms through recognition
and repair are generally shared with its cis derivatives since it forms same or similar adducts with
DNA and is recognized by the proteins responsible for the repair mechanisms. Interestingly, this
cross-resistance was less for oxaliplatin, which is thought to be a result of additional steric
hindrance presented by the diamocyclohexane (DACH) carrier ligand (43,44,45).
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Figure 1.7. Structures of trans-PtTz, trans-[PtNH3(thiazole)Cl2], and BBR3464, [{trans-PtCl(NH3)2}2(µtrans-Pt(NH3)2{NH2(CH2)6NH2}2)]4+

In contrast, structurally unique trans-platinum planar amine (TPA) and polynuclear
platinum compounds (PPC), resulted in unaltered cytotoxic activities in both cisplatin and
oxaliplatin-resistant cells (46,47,48,49). This was exemplified with trans-PtTz and BBR3464
(Figure 1.7), which were demonstrated to bypass cisplatin recognition and repair mechanisms to
cause unaffected cytotoxic activities in resistant cells by binding to DNA in distinct manners
(50,51). Therefore, to develop a compound with a superior or wider spectrum of antitumor efficacy,
a compound needs to be designed to interact with DNA in a manner different than cisplatin and its
analogues (52).

1.6 Nontraditional Platinum Compounds
1.6.1 trans-Platinum Planar Amine (TPA) Compounds

Figure 1.8. Structure of cisplatin and transplatin

After the discovery of cisplatin, the cis configuration of Pt(II) compounds was extensively
studied, since early structure-activity studies showed that a cis configuration of the two leaving
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groups is essential for antitumor activity of simple Pt(II) derivatives. This has also been confirmed
for several groups of compounds (7,8) and the trans configuration was believed to be clinically
inactive (8,53,54,55,56). It is generally accepted that the trans isomer of cisplatin is inactive due
to two major factors: kinetic instability allowing faster deactivation and lack in its ability to induce
DNA structural perturbation. However, several classes of trans-Pt compounds violated this rule
and exhibited remarkable cytotoxic activities by interacting with DNA in a unique manner.
Furthermore, they were active in tumor cells resistant to cis analogues (57,58,59). Among such
complexes are those with bulky N-donor aromatic heterocycles, iminoethers, cyclohexylamine,
and aliphatic amines (60). These cytotoxic trans platinum complexes induce qualitatively and
quantitatively different DNA adducts, indicating that cisplatin-like DNA adducts are not
mandatory determinants for antitumor activity of platinum compounds (61).

Table 1.1. Summary of cisplatin resistance mechanism and the circumvention of the resistance with
TPA carboxylates compounds.

Molecular Mechanism

References

Circumvention of the
drug resistance with
TPA

References

Inactivation of cisplatin by (62,63,64)
sulfur nucleophiles

Enhanced stability

(65,66)

Reduced accumulation by
changing the profile of
influx/efflux

(27,67,68,69)

Enhanced cellular
accumulation

(50,70,71,58)

Increased repair/tolerance/
removal and failure of
apoptotic pathways

(72,73,74,75,76) Formation of different PtDNA adducts. Different
cell death mechanism
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(58,77,78,79,80)

As described in the previous section, the major obstacle of current platinum chemotherapy is
the occurrence of inherent and acquired resistance of tumor cells, and it is of considerable interest
to identify an active compound in the resistant cells. The known mechanisms of cisplatin resistance
are shown in Table 1.1 and TPA compounds circumvented these mechanisms by demonstrating
higher stability to sulfur nucleophiles, enhanced cellular accumulation, and formation of different
Pt-DNA adduct ultimately leading to distinct cell death (Table 1.1).
The trans-isomer of cisplatin, transplatin (trans-[Pt(NH3)2Cl2]), does not exhibit a
comparable chemotherapeutic effect and is considered clinically inactive. When one or both of the
NH3 groups in transplatin are replaced to a sterically hindered planar amine ligand, the compound
exhibits micromolar cytotoxicity equivalent to that of cisplatin and retains cytotoxicity toward
cisplatin- and oxaliplatin-resistant cell lines. A possible explanation for this retained cytotoxic
activity is associated with its distinct DNA binding profile exhibited by the trans-platinum
compounds (50,81).

Figure 1.9. Cross-links formed by trans-PtTz. From Ref (82)
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Table 1.2. Summary and comparison of structural characteristics of DNA cross-links of trans[PtCl2(NH3)(thiazole)], transplatin, and cisplatin. From Ref (50).

The unique DNA binding of TPA was exemplified with trans-PtTz as shown in Figure 1.9
and Table 1.2. trans-PtTz exhibited significantly higher formation of interstrand cross-links with
DNA compared to cisplatin or transplatin (83). The steric effects of these planar ligands resulted
in the formation of structurally unique cross-links, which may be the main cause of its unique
cellular effects being significantly different from that of cisplatin. Despite high antitumor activity
and distinct mode of binding, trans-PtTz is more reactive than the cis-isomer due to high transinfluencing chlorides trans to one another, whereas this increased reactivity potentially increases
its susceptibility to inactivation by sulfur nucleophiles. This is likely to have a major influence in
the biological activities of TPA and further optimization is made to address this pharmacokinetic
problem.

Figure 1.10. Rational design of TPA compounds.
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To further optimize the pharmacological properties of the TPA compounds, the chloride
leaving group can be replaced with carboxylate leaving groups. This greatly enhances aqueous
solubility and stability to hydrolysis while retaining the cytotoxicity of the parent chloride
compounds (65,70,84,71). The utilization of a carboxylate leaving group was previously
exemplified with carboplatin and oxaliplatin by utilizing bi-dentate carboxylate leaving groups to
significantly enhance their stability compared to cisplatin. TPA carboxylates utilizes two monodentate carboxylate leaving groups of TPA compounds in trans position to another, which allows
enhanced stability due to the weak trans influencing nature of the carboxylate leaving group. This
strategy is rather novel and further reactivity optimization of TPA is necessary to identify a
clinically relevant chemotherapeutic platinum agent.

1.6.2 Polynuclear Platinum Compounds (PPC)

Figure 1.11. Structure of BBR3464.

In efforts to differentiate the DNA binding of platinum compounds from cisplatin, another
innovative approach was achieved by the syntheses of cationic polynuclear platinum complexes
(PPC). These compounds contain two or three platinum centers with both cis and trans
configurations connected by polyamine linkers. A representative trinuclear complex, 4+ charged
BBR3464, is the first polynuclear platinum compound to enter clinical trials as an anticancer agent.
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BBR3464 showed promising results by demonstrating higher cellular uptake and exhibiting up to
hundred fold increase in potency on a molar dosage than cisplatin. BBR3464 also showed
unaffected potency in cisplatin-resistant and p53 mutant tumors (85,86,87,88,89,90).

Figure 1.12. Structures from molecular modeling of the major DNA adducts of BBR3464. From Ref
(82).

The overall DNA binding profile of BBR3464 is significantly different from that of
cisplatin. Due to the positively charged nature of polynuclear platinum compounds, the molecule
initially interacts through noncovalent interaction, where this interaction allows the DNA binding
to be significantly more rapid than that of cisplatin (91). Then it forms various unique long-range
interstrand and intrastrand bifunctional cross-links as shown in Figure 1.12 (51,92). The unique
properties of long-range interstrand cross-links of BBR3464 and resulting conformational
alterations in DNA showed critical consequences for their antitumor effects. The platinum-DNA
adducts resulted from the unique mode of binding are not recognized by high mobility group
domain proteins (HMG) and are a poor substrate for nucleotide excision repair (NER). HMG and
14

NER proteins are known to be responsible for the recognition and repair of cisplatin-DNA adduct
and this may explain the unaffected cytotoxic activities seen in cisplatin resistant cells (92).
Although BBR3464 resulted in a non-cross resistant cytotoxicity with cisplatin by inducing
a distinct mode of DNA binding, degradation into inactive metabolites by sulfur nucleophile was
no exception for BBR3464 as with other covalently binding platinum compounds. Despite its
success demonstrated in pre-clinical and Phase I clinical studies, results from Phase II clinical
studies revealed a rapid degradation of BBR3464 into inactive metabolites due to higher plasma
protein binding in man than in mice. These pharmacokinetic factors have discouraged the use of
BBR3464 in the clinical setting (93,94).

1.6.3 Noncovalently Binding Cationic Polynuclear Platinum Compounds (PPC-NC)

Table 1.3. Summary and comparison of structural characteristics of Pt-DNA adducts of different
classes of platinum compounds.

Platinum
Compounds

Examples

Predominant Pt-DNA
Adducts

References

Cisplatin and its
analogues

Cisplatin
Carboplatin
Oxaliplatin

Short-range intrastrand (1,2)
cross-links

(95,96)

TPA Compounds

trans-Pt[(Cl2)(NH3)(Tz)],
trans-Pt[(L)(L’)(NH3)(X2)

Short-range interstrand
cross-links

(97,98)

Covalently Binding
Polynuclear Platinum
Compounds (PPC)

BBR3464
1,1/t,t

Long-range interstrand (1,4)
cross-links

(51,99,100)

Noncovalently
Binding Polynuclear
Platinum Compounds
(PPC-NC)

Triplatin NC

Noncovalent interactions
with negatively charged
phosphate backbone

(101,102)
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Traditional platinum chemotherapeutic agents, cisplatin and its analogues, all form
predominantly short-range intrastrand crosslinks on DNA to cause severe conformational
distortions, which is a critical determinant of the biological consequence of the platinum
chemotherapeutic treatment. The structurally distinct trans-isomer, TPA compounds and
polynuclear platinum compounds (PPC) form short-range interstrand cross-links and long-range
interstand cross-links with DNA, respectively (summarized in Table 1.3). By exhibiting these
distinct modes of DNA binding, the cellular resistance to cisplatin involving enhanced DNA
recognition and repair was minimized. One drawback of all covalently binding platinum
compounds are their susceptibility to the drug inactivation by binding to sulfur nucleophiles.

Figure 1.13. Structures of trinuclear platinum compounds.

While studying the long-range cross-links with BBR3464 in DNA, a pre-association of the
central platinum moiety in the minor groove through noncovalent interaction was observed (92).
To solely study the noncovalent interactions of PPC, the reactive chlorides were replaced with
inert ammine ligands and later it was discovered that these inert platinum compounds exhibit
antitumor properties (103,104). This novel approach, achieved by replacing reactive chloride
leaving group of BBR3464 with substitutionally inert ammine ligand (NH3) or “dangling” amine
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(NH2(CH2)6NH3) (Figure 1.13) to produce inert polynuclear platinum agents, completely negated
the pharmacokinetics problems of covalently binding platinum compounds due to absence of any
covalent binding site (105,103).
Noncovalently binding polynuclear platinum compounds (PPC-NC) demonstrated
interesting biological properties including in vitro cytotoxicity and high cellular accumulation in
various tumors cells including cisplatin-resistant and p53 mutant cells (106,107). Contradicting
the previous assumption that the platinum compounds have to be neutral or hydrophobic to enter
the cells more efficiently, Triplatin NC (8+) demonstrated much higher cellular accumulation than
those of cisplatin and BBR3464 (4+) (54). Interestingly, Triplatin NC (8+) showed higher
cytotoxicity and cellular accumulation than its congener AH44 (6+) despite its higher charge,
suggesting a trend that higher charged polynuclear platinum compounds generally demonstrate
superior anticancer properties (106).
Yet, PPC-NC and their structure-activity relationships (SAR) have not been explored
thoroughly. A further investigation is deserved to establish the SAR including the effects of charge,
number of platinum centers, and type of inert ligands on antitumor properties to develop clinically
relevant noncovalently binding platinum chemotherapeutics. Moreover, their drug mechanism
including the overall profile of DNA interaction, mechanism of cellular internalization, and
mechanism of cell death should be investigated further.
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1.7 Aim and Scope of This Thesis
Platinum anticancer compounds with cis geometry, similar to cisplatin, have been explored
to circumvent the cisplatin resistance; however, they were not considered broadly active in
cisplatin cells due to exhibiting similar or same cell death mechanism as cisplatin. Platinum
compounds with trans geometry were less studied due to transplatin being clinically inactive; but
with few structural modifications, they resulted in unaffected cytotoxic activities in cisplatin
resistant cells with structural modification by exhibiting different modes of DNA binding. This
thesis focuses on further exploring and establishing structure-activity relationship of two
promising non-classical series of platinum compounds with trans-geometry: trans-platinum planar
amine (TPA) compounds and noncovalently binding polynuclear platinum compounds (PPC-NC).
In Chapter 2, further optimizations of the reactivity of TPA compounds are accomplished
by modifying the leaving carboxylate groups. The effects of modified reactivity are probed by a
systematic combination of chemical and biophysical assays, followed by evaluating their
biological effects in cells (Chapter 3). Mono-, Di-, Tri-, and Tetraplatin NC with charge of 4+,
6+, 8+, and 10+ are synthesized in Chapter 4 to establish the structural-activity relationship of
PPC-NC by expanding the series. These compounds are evaluated by observing their overall DNA
binding profiles, cellular accumulation, and cytotoxic activities (Chapter 5). Other works
accomplished throughout the years in the graduate program are reported in Chapter 6.
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Chapter 2

Synthesis, Characterization,
and Chemical Property of TPA
Compounds
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CHAPTER 2.

SYNTHESIS, CHARACTERIZATION, AND

CHEMICAL PROPERTY OF TRANS-PLATINUM PLANAR AMINE
COMPOUNDS

Figure 2.1. General structure of TPA compounds. L = NH3 or planar amine, L' = planar amine, X = Cl,
carboxylate.

trans-Platinum planar amine compound (TPA) is considered as a strong candidate to
circumvent cisplatin resistance by demonstrating enhanced stability and forming distinct Pt-DNA
adducts. Further investigations on structural-activity relationships are necessary to ultimately
develop a clinically useful drug. The general structure of TPA compounds is trans-Pt[X2(L)(L’)],
where L and L’ are the carrier group (L= NH3, planar amine, L’= planar amine and X being the
leaving group (chloride, carboxylates) (Figure 2.1). Based on previous observations, the reactivity
of the TPA compounds can be modulated by modifying the carboxylate leaving group; and the
formation of Pt-DNA adduct can be controlled by utilizing different planar amine carrier ligands
(thiazole, pyridine, picoline, isoquinoline, etc.). This “fine-tuning” strategy of TPA is further
explored in this chapter to identify a compound with superior therapeutic efficacy, where a balance
between cytotoxic activities and inactivating interactions is accomplished.
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2.1 Structure-Based Rational TPA Drug Design
2.1.1 Effects of Planar Amines Carrier Ligands on Cytotoxicity

Table 2.1. IC50 values of platinum compounds in HCT116 human colon carcinoma. From Ref (71).

A previous study (Table 2.1) shows that trans-[Pt(O2CH2)2(NH3)(Isq)] exhibited higher
cytotoxicity while the TPA compounds with 4-picoline carrier ligand required higher dosage to
cause equivalent amounts of cell death (71). The result suggests that the choice of planar amine
carrier ligand is critical in terms of cytotoxicity, where larger and greater steric hindrance
isoquinoline ligand resulted in higher cytotoxicity compare to picoline or pyridine compounds.
This trend was also confirmed with other studies, where the order of cytotoxicity exhibited for
different carrier ligands with acetate leaving group were found to be as following (highest to
lowest): Isoquinoline > 2-picoline > 4-picoline > pyridine (71,84). These results suggest to utilize
isoquinoline as a carrier ligand for further developments and investigations.

21

2.1.2 Effects

of

Carboxylate

Leaving

Groups on

Cytotoxicity

and

Cellular

Accumulation

Figure 2.2. Influence of serum binding on platinum cellular uptake in A2780 ovarian carcinoma.
A2780 cells were treated with 10 µM cisplatin and TPA compounds before and after pretreatment with
serum. From Ref (63).

Previously, it was shown that the nature of the carboxylate affects the cytotoxicity even in
closely related compounds. These results are shown in Table 2.1, where the compound with more
reactive formate has shown significantly higher cytotoxicity than that with more stable acetate.
Figure 2.2 shows that carboxylate leaving group also affects cellular accumulation and metabolic
stability of the TPA compounds. Figure 2.2 shows the cellular accumulation of TPA compounds
measured in A2780 ovarian carcinoma before and after serum incubation. Serum is a liquid portion
of blood, where most of the inactivation of the platinum compounds occurs due to presence of
sulfur nucleophiles (e.g. serum albumin). Although all of the TPA with carboxylates were shown
to be significantly more stable than cisplatin, TPA compounds with higher reactivity (formate)
resulted in higher cellular accumulation while demonstrating less stability to the protein binding.
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From these findings, it is suggested that the reactivity of carboxylate leaving group on TPA
contributes crucially to the cytotoxicity, cellular accumulation, and metabolic stability. These
results convey the need to further modulate the reactivity of carboxylate leaving groups in efforts
to identify carboxylate ligands with optimal pharmacological properties in a clinical environment.
To expand our series, moderately reactive hydroxyacetate and lactate are utilized and examined.

2.2 Synthesis and Characterization
The synthesis of TPA compounds is adopted and modified from a method published previously
(70) .

Figure 2.3. Synthetic scheme of TPA compounds. L= 4-picoline, isoquinoline; R=H (Formate), R=CH 3
(Acetate), R=CH2OH (Hydroxyacetate), R=CHCH3OH (Lactate).

Starting Material- Cisplatin was synthesized by using a method published previously (108). All
the chemicals and solvents were purchased from common vendors and used as supplied.

Preparation of trans-[Pt(L)(NH3)I2]
Cisplatin (1 mmol) was suspended in 10 mL of water and AgNO3 (2 mmol) was added to the
platinum solution. A solution of planar amine (2 mmol) was prepared in methanol and then added
to the platinum solution. The mixture was stirred overnight in the dark. Next day, the mixture was
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stirred under reflux conditions for 4 h to complete the reaction. Then the hot solution was filtered
through celite to remove silver chloride formed during the reaction. Excess amount of KI (3 mmol),
dissolved in water, was added to the solution and the mixture was subsequently evaporated to
dryness. The white crude was suspended in ethanol and heated to reflux temperature during 4 h.
Orange solid was isolated and washed with water, methanol, and ethyl ether.

trans-Pt[(4-pic)(NH3)I2]. 1H NMR((CD3)2CO): δ 8.7(d, 2H), 7.2(d, 2H), 3.7( s, 3H), 2.4(s, 3H.)
Anal. Calc’d for C6H10N2I2Pt: C 12.89, H 1.80, N 5.01. Found: C 13.08, H 1.68, N 5.04

trans-Pt[(isq)(NH3)I2]. 1H NMR((CD3)2CO): δ 9.6 (s, 1H), 8.7(d,1H), 8.3(d, 1H), 8.1(d, 1H),
7.9(d, 1H), 7.6(m, 2H). Anal. Calc’d for C9H10N2I2Pt: C 18.17, H 1.69, N 4.71. Found: C 18.32,
H 1.66, N 4.49.

Preparation of trans-[Pt(L)(NH3)(COOR)2],R=CH3, CHCH3OH.
1 mmol of trans-Pt[I2(L)(NH3)] complex was suspended in water 1.98 equivalent of freshly
synthesized AgCOOR was added to the platinum solution and was stirred overnight in dark at
60 °C. The hot solution was filtered through celite to remove silver iodide formed and the solution
was evaporated to dryness. White solid was recrystallized in MeOH/Ether. If the product turned
brown or grey, it was dissolved it in a minimum amount of water and filtered through celite to
remove any impurities.

Preparation of trans-[Pt(L)(NH3)(COOR)2], R=H, CH2OH.
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2.2 mmol of formic acid was dissolved in minimum amount of water. 1 mmol of Ag2O was added
to the solution. The mixture was stirred in dark for 8 h until black solid (Ag2O) was no longer
present in the solution. To the solution, 1 mmol of trans-Pt[(L)(NH3)(I)2] complex was added and
was stirred in dark overnight. Next day, the mixture was filtered through celite to remove AgI
formed during the reaction. The filtrate was dried under vacuum and acetone added to precipitate
out white solids. The product was collected through membrane filter then washed with acetone
and ether to remove any free carboxylic acid.

If the product turned brown or grey, they were

dissolved it in minimum amount of water and filtered through celite to remove any impurities.

Figure 2.4. Structure of trans-platinum planar amine (TPA) compounds synthesized.

[1] 1H NMR(D2O): δ 8.3(d, 2H),7.45(s, 2H), 7.3(d, 2H), 2.25(s, 3H), Anal. Calc’d for C8H12N2O4Pt:
C 24.31, H 3.06, N 7.09. Found: C 24.13, H 3.06, N. 7.15
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[2] 1H NMR(D2O): δ 8.3(d, 2H), 7.3(d, 2H), 2.5(s, 3H), 1.75(s, 6H). Anal. Calc’d for
C10H16N2O4Pt: C 28.37, H 3.81, N 6.62. Found: C 28.09, H 3.68, N 6.41

[3] 1H NMR(D2O): δ8.3(d, 2H), 7.3(d, 2H), 4.1(s, 4H), 2.45(s, 3H).

Anal. Calc’d for

C10H16N2O6Pt: C 26.38, H 3.54, N 6.15. Found:C 26.12, H 3.23, N 6.01.

[4] 1H NMR(D2O): δ8.3(d, 2H), 7.3(d, 2H), 4.1(q, 2H), 1.1(d, 6H). Anal. Calc’d for C12H20N2O6Pt:
C 29.82, H 4.17, N 5.80. Found:C 29.72, H 4.23, N 5.91.

[5] 1H NMR(D2O): δ9.2(s, 1H), 8.3(d, 1H), 8.15(d, 1H), 7.8-8.0(m, 4H) 7.3(s,2H). Anal. Calc’d
for C11H12N2O4Pt: C 30.63, H 2.80, N 6.49. Found:30.32, H 2.76, N 6.32.

[6] 1H NMR(D2O): δ 9.2(s, 1H), 8.3(d, 1H), 8.1(d, 1H), 7.8-8.0(m, 4H), 2.0(s, 6H).
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Pt NMR

(D2O): -1443. Anal. Calc’d for C13H16N2O4Pt: C 33.99, H 3.51, N 6.10. Found: C 33.95, H 3.27,
N 5.80

[7] 1H NMR(D2O): δ 9.0(s, 1H), 8.1(d, 1H), 8.0 (d, 1H), 7.9(d, 1H), 7.8(d, 1H), 7.7(t, 1H), 7.6(t,
1H), 3.9(s, 4H).
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Pt NMR (D2O): -1441. Anal. Calc’d for C13H16N2O6Pt: C 31.78, H 3.28, N

5.70. Found: C 31.61, H 2.93, N 5.64.

[8] 1H NMR(D2O): δ 9.0(s, 1H), 8.1(d, 1H), 8.0 (d, 1H), 7.9(d, 1H), 7.8(d, 1H), 7.7(t, 1H), 7.6(t,
1H), 4.1(q, 2H), 1.1(d, 6H).

195

Pt NMR (D2O): -1450. Anal. Calc’d for C15H20N2O6Pt: C 34.69,

H 3.88, N 5.39. Found: C 34.22, H 3.51, N 5.26.
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2.3 Evaluation of TPA Compounds by Chemical Techniques

Figure 2.5. Structures of TPA compounds studied.

To evaluate the effects of carboxylate modification on TPA compounds, chemical properties
of TPA compounds including hydrolysis rate, solubility, and rate of interaction with sulfur
nucleophiles are assessed in this section. Here, with an isoquinoline as a carrier ligand, moderately
reactive carboxylate leaving groups, hydroxyacetate (TPA2) and lactate (TPA3), are observed in
contrast to previously studied acetate compound (TPA1) to further modulate and optimize the
reactivity of the compounds (Figure 2.5) (66).
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2.3.1 Experimental Condition
Aqueous solubility
Solubility was measured by sequential addition of water and agitation for 15 min until solution
was no longer clear. The results were determined from an average of 3 trials.
Hydrolysis rate
For hydrolysis studies, 10-3 mM complex was dissolved in 1 mL of nanopure water. The pH values
of the samples were controlled in regular intervals and readjusted if necessary by addition of HNO3
(1, 0.1, 0.01 M) or NaOH (1, 0.1, 0.01 M). Aliquots of 20 mL were taken from the bulk solution
for HPLC analysis. The aquated species were identified by comparison with the hydrolysis profile
produced by the corresponding (labile) nitrate compounds.

Reaction with N-Acetyl-Methionine by 1H NMR Spectroscopy
Platinum compounds were incubated with N-acetyl-methionine in a reaction ratio of 1:2 (platinum
complex: N-acetyl-methionine) in D2O. 1H NMR at various time points up to 16 h was recorded
on a Varian Mercury series 300 MHz NMR spectrometer using a 5 mm probe. 1H NMR spectra
were referenced to sodium 3-(trimethylsilyl)-propionate (TSP) at d = 0 ppm. Approximate halflives (t1/2) of each reaction were calculated by plotting the integral ratio of unreacted vs. reacted
products. Approximate half-life is defined as time when 50% of starting material was converted to
methionine bound product.
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2.3.2 Results
Table 2.2. Initial hydrolysis rate, aqueous solubility, and methionine binding rate of TPA compounds.
Values in parentheses are from ref (66), where the values were obtained in PBS buffer.

Compound
t-[Pt(formate)2(isq)(NH3)]
TPA1
TPA2
TPA3

Initial Hydrolysis
Rate, k1 (s-1)
7.4 x 10-7
5.7 x 10-7
5.7 x 10-7

Aqueous
Solubility
(mg/mL)
1.5
6.7
1.6
4.3

Methionine Binding
Rate (t1/2, h)
(2.6)
20.4 (10.7)
10.6
15.4

Aqueous solubility is one of the important parameters to achieve desired concentration of
drug in a systemic circulation for achieving required pharmacological response (109,110).
Carboxylate leaving group was shown to enhance water solubility of the TPA compounds and their
solubility was measured and the results are shown in Table 2.2. TPA compounds demonstrated
enhanced aqueous solubility compared to the chloride analog, although it was not significantly
enhanced due to presence of hydrophobic isoquinoline ligand.

The mutually weak trans influence of the carboxylate ligands resulted in significantly less
reactive compounds than the chloride analogs and the reactivity of the TPA were evaluated by
measuring the initial hydrolysis rate (k1) (Table 2.2). These results may be contrasted with
transplatin (k1 = 1.9 x 10-4) and cisplatin (k1 = 5.2 x 10-5), where the rate of hydrolysis for TPA
carboxylates are significantly slower than those containing chloro ligands by 2-3 orders of
magnitudes (111,112).
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Figure 2.6. Structures of N-Acetyl-Methionine.

To evaluate the reactivity of TPA compounds further, substitution rates with N-acetyl–
methionine (NAM) was measured. Methionine is a thioether containing amino acid that is
abundant in human proteins (113,114). It is used as a probe to measure the rate of platinum drug
inactivation by sulfur-containing nucleophiles.

Figure 2.7. Substitution reaction of TPA3 with N-acetyl-methionine (1:2) followed by 1H NMR
spectroscopy. a. shift of the H2 of isoquinoline. b. formation of free carboxylate.
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The reactions of TPA compounds with thioether containing NAM amino acid were
monitored by observing the shift of the H2 proton of isoquinoline from δ = 9.03 ppm to 9.59 ppm,
where the shift is a result of carboxylate leaving group substitution with NAM to form PtN2S2
(Figure 2.7a). This can be also confirmed by monitoring the shift of the protons of carboxylate
leaving group from δ =1.06 (platinum bound) to δ = 1.2 (free carboxylate) (Figure 2.7b). The
approximate half-lives (t1/2) of each reaction were calculated based on the peak integration of the
H2 proton of isoquinoline, and the values found were calculated to be 20.4 h, 10.6 h, and 15.4 h
for TPA1, TPA2, and TPA3, respectively (Table 2.2). With previously published results (66), the
rate of reactivity to NAM can be listed as the following (highest reactivity to lowest): formate >
hydroxyacetate > lactate > acetate. It is interesting to note that the hydroxyacetate (TPA2) which
contains a hydroxyl functional group, showed higher reactivity than the compounds with acetate
(TPA1); while the lactate (TPA3) with an additional methyl group showed a decrease in reactivity
compared to the compounds with hydroxyacetate (TPA2).

2.4 Binding of TPA Compounds with DNA
DNA is the primary pharmacological target of the platinum-based anticancer agents and is
considered as the most crucial factor in determining the potency of platinum chemotherapeutics,
since the structural disturbance of DNA induced by platinum compounds is known to be the
primary mechanism of its cell death. Transplatin was shown to induce a significant amount of
DNA platination in previous studies (115). Yet, DNA platination does not always lead to
perturbation of the DNA structure since the perturbation of the DNA structure heavily depends on
the type of Pt-DNA adducts formed (71,58,116).
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In this section, the perturbation of DNA structure induced by
TPA compounds was evaluated by a competitive ethidium
bromide (EtBr) fluorescence assay. The fluorescent probe,
EtBr, is a DNA binding fluorescent dye that intercalates into
the minor groove of DNA with no sequence preferences
(117,118). Binding of fluorescent probe EtBr to DNA by
Figure 2.8. Structure of Ethidium
Bromide (EtBr)

intercalation is blocked in a stoichiometric manner by

structure perturbation induced by platinum compounds including cisplatin, which results in a loss
of fluorescence intensity (119,120). This competitive assay can also be used to distinguish between
perturbations induced in DNA by mono- and bi-functional adducts of platinum compounds (121),
where mono-functional adducts do not perturb the DNA structures to prevent the intercalation of
EtBr.
As a parallel experiment, the melting temperature of DNA modified by platinum
compounds measures the qualitative effect of platinum compounds on DNA thermal stability,
where cisplatin-DNA crosslinks are known to reduce the thermal stability of DNA (122,123). The
frequency and nature of Pt-DNA adducts are crucial parameters contributing to cytotoxic activity
and these biophysical assays with DNA are useful tools to predict biological consequences of the
platinum compound, thereby contributing to the rational basis for designing and screening of new
candidates for platinum chemotherapeutic agents.
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Figure 2.9. Dependencies of (a). ethidium bromide fluorescence and (b). melting temperature on rb
(drug to nucleotide ratio) for DNA modified by various platinum complexes in 10 mM NaClO4 at 37 °C
for 48 h. (X) cisplatin; (●) transplatin; (∆) [PtCl(dien)]Cl; (○) trans-[PtCl2(NH3)(quin)]. From Ref (124).

In a previous study, the TPA chloride analog, trans-[Pt(Cl2)(NH3)(quin)], significantly
decreased EtBr fluorescence (Figure 2.9a) and melting temperature (Figure 2.9b) showing similar
ability to perturb DNA structure to that of cisplatin (124). These fluorescence quenching effects
were not observed with mono-functional [PtCl(dien)]Cl and transplatin due to their lack of ability
to induce DNA structural perturbation (124,125). To assess DNA structural perturbation induced
by TPA compounds to cause DNA structural perturbation, TPA compounds synthesized in this
chapter were evaluated by using EtBr competitive and DNA melting temperature assay.

2.4.1 Experimental Conditions
Ethidium Bromide Fluorescence Quenching Assay
Calf Thymus DNA (100 μM) was incubated with the compounds for 48 h at 37 ºC followed by
treatment with ethidium bromide (EtBr) at ri values from 0.05 to 0.25. The experiments were
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carried out in 10 mM NaClO4 in the presence of 0.4 M NaCl to avoid secondary binding of the
EtBr to DNA (121,124). Samples were irradiated with 525 nm light and emission was recorded at
600 nm with a scan rate of 600 nm/min at 25 ºC. The results were determined from an average of
3 trials.

Melting Temperature of CT-DNA Modified with TPA compounds
200 μM calf thymus DNA samples (expressed as nucleotides) were incubated with the platinum
complexes at various ratios (ri= 0 to 0.05; ri being the ratio of drug per nucleotide) in 10 mM
NaClO4 at 37 °C for 24 h. To avoid the formation of air bubbles during the experiment the samples
were degassed by stirring under vacuum for 5 min. The absorbance at 260 nm was recorded while
the temperature was increased from 40 or 60 to 95 °C at a rate of 0.5 °C/min. A low headspace
cuvette with 10 mm path length filled with 150 μL sample was used to minimize solvent
evaporation. The resulting melting curves were normalized and the melting temperature was
determined by sigmoidal curve fitting using Microsoft Excel. Experiments were performed in
duplicate.
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2.4.2 Results

Figure 2.10. Quenching of ethidium bromide fluorescence intensity upon treatment with platinum
compounds after 48 h incubation.

Figure 2.11. DNA melting temperature of TPAs. 200 μM calf thymus DNA samples (expressed
as nucleotides) were incubated with the platinum complexes at various in 10 mM NaClO 4 at
37 °C for 24 h.
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EtBr assay with TPA compounds showed a minor loss in fluorescence intensity while
cisplatin showed significantly higher loss of the fluorescence intensity (Figure 2.10). These results
were consistent with DNA melting temperature assay (Figure 2.11), where the melting
temperature of DNA did not significantly alter after the treatment with TPA compounds. From
these results, it is suggested that the rates of DNA perturbation structure caused by TPA
compounds were much slower than cisplatin and trans-[Pt(Cl2)(NH3)(quin)] due to enhanced
stability of the drug. This similar effect was previously seen with carboplatin (126).
A combination of chemical experiments showed that TPA lactate and hydroxyacetate
compounds exhibited moderate reactivity in comparison with previously utilized acetate and
formate. Biophysical studies of the TPA compounds synthesized in this chapter with DNA showed
that they do not readily perturb the structure of DNA, which may be a result of their enhanced
stability. Cellular consequences of the modulated reactivity are investigated in the next chapter by
assessing their biological effects in cells.

2.5 Contributions
All of the work in this chapter was done by Daniel E. Lee with exception of hydrolysis rate and
solubility rate, which were done by Erin Ma.
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Chapter 3

Biological Effect of TPA
Compounds
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CHAPTER 3.

BIOLOGICAL EFFECT OF TPA COMPOUNDS

In the previous chapter, the reactivity of TPA compounds were modulated by modifying the
structures of the carboxylate leaving group. To develop a clinically relevant platinum-based
chemotherapeutic which can circumvent cisplatin resistance, it is crucial for the compound to
exhibit cytotoxic activities and high cellular internalization while demonstrating enhanced stability
to metabolic inactivation by sulfur nucleophiles. To examine these biological parameters and to
understand the biological consequences of modulated TPA reactivity, biological assays including
cytotoxicity, cellular accumulation, and cell cycle effects were evaluated.

Figure 3.1. MTT assay to measure cell survival and proliferation.

Cytotoxicity is considered as a primary criterion to measure potency of platinum
chemotherapeutics. The effects of TPA on cell proliferation were measured by using MTT assay
in tumor cells. This yellow tetrazole is reduced to violet formazan through mitochondrial reductase
in living cells and is commonly used to as a quantitative colorimetric assay for mammalian cell
survival and proliferation (127,128). The potency is commonly expressed as IC50, or the drug
concentration required to inhibit 50% of the maximal cell growth.
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Cellular accumulation, which is a net measure of influx and efflux, is another critical criterion
contributing to cytotoxic activity (129,130). It is also worthwhile to mention that acquired and
inherent resistance to traditional platinum compounds involves reduced cellular accumulation,
which could result from increased efflux, reduced influx, and/or degradation into inactive
metabolites by sulfur nucleophiles (68,131,132). The cellular accumulation of platinum based drug
can be measured by treating cells with the platinum compounds and measure the amount of
platinum in cells by using atomic absorption or inductively coupled plasma- mass spectroscopy
for quantitative analysis.
Another biological effect to investigate is cell cycle effects induced by TPA compounds. It is
well recognized that DNA damage induced by cisplatin usually activates cell cycle checkpoints,
which inhibit cell cycle progressing, where the inhibition results in depletion of G1 phase and S
phase accumulation in cisplatin-sensitive ovarian carcinoma A2780 cells (133,134,135,136).
Previously, TPA compounds retained their activities in cisplatin-resistant and p53 mutant cells,
which may indicate that their toxicity might be mediated by mechanisms differ from cisplatin. To
confirm this, the cell cycle effects induced by TPA compounds were examined in this chapter.

3.1 Cytotoxicity, Cellular Accumulation, and Metabolic Stability of TPA
Compounds

3.1.1 Experimental
Cell Culture
The human ovarian cancer cell line, A2780 was grown in monolayer culture in RPMI 1640
(Invitrogen, Grand Island, NY, USA; Cat# 11875-093) supplemented with 10% fetal bovine serum
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(FBS, Quality Biologicals, Gaithersburg, MD, USA; Cat# 110-001-101US) and 100 U/mL
penicillin and 100 mg/mL streptomycin (Invitrogen, Grand Island, NY, USA; Cat# 15140), at
37 °C in a 5% CO2 incubator.

Growth Inhibition Assay
Five thousand cells/well in 100 µL were seeded in a 96-well plate and allowed 24 h to attach.
A2780 cells were then treated with the TPA compounds for 72 h. Following TPA compound
removal, the cells were incubated in the presence of 0.5 mg/mL MTT reagent [(3,4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Sigma–Aldrich, St. Louis, MO, USA;
Cat# M2128] in RPMI medium for 3 h at 37°C. The MTT reagent was removed and 100 µL DMSO
was added to each well. The plate was then incubated on a shaker at room temperature in the dark.
The spectrophotometric reading was taken at 570 nm using a microplate reader. For the time
dependent serum incubation studies, 1 mM of each Pt compound was incubated in FBS for 0, 24
and 48 h (final concentration of 500 μM). The cells were then treated with the serum pre-incubated
compounds at a concentration range of 0.78 – 50 μM for 24 h.

Cellular Accumulation of Platinum Compounds
A2780 cells were treated with 10 µM of platinum compounds following incubation with or without
serum for 48 h. After 12 h treatment with each compound, cells were harvested. To digest samples,
1 mL of concentrated HNO3 was added to the pellet and left to digest for three days. 2 mL of water
was then added to dilute the samples and the solutions were filtered through a 0.45 μGHP filter,
and analyzed on ICP-MS to determine the platinum concentration. Error bars indicate Mean ±
S.E.M. (the standard error of the mean) from two independent experiments.
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3.1.2 Results

Figure 3.2. Cytotoxicity curve of TPA compounds and cisplatin before and after incubation with
serum in A2780 cells. Platinum compounds were incubated with fetal bovine serum for 24 h and 48 h
then treated cells for 72 h. Growth inhibition was then measured by MTT after drug treatment.

Table 3.1. Cytotoxicity of TPA compounds and cisplatin before and after incubation with serum in
A2780 cells.

Compound

IC50 (μM)
Control

24 h Serum
Incubation

48 h Serum
Incubation

Fold Increase in
IC50 (48 h)

Cisplatin

1.08 ± 0.1

7.95 ± 0.07

28.3
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TPA1

23.5 ± 1.5

31.1 ± 3.7

36.1

1.5

TPA2

11.4 ± 0.9

13.5 ± 2.8

16.4

1.6

TPA3

14.8 ± 3.1

16 ± 0.5

21.2

1.4
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Figure 3.3. Structures of TPA compounds studied.

Therapeutic efficacy of platinum chemotherapeutic agents is reflected as a balance between
metabolic inactivating interactions and biological consequences of DNA toxicity; therefore,
cytotoxic activity and metabolic stability were measured to assess the efficacy of TPA compounds
as potential new chemotherapeutic agents (137). To assess the metabolic stability of TPA
compounds with modified carboxylates, IC50 values for the TPA compounds were obtained by
using MTT assay in A2780 ovarian carcinoma since ovarian cancer cells are known to be sensitive
to platinum chemotherapeutics treatments. All of the TPA compounds exhibited low micromolar
cytotoxicity similar to that of cisplatin as shown in Figure 3.2. Among all, the highest cytotoxicity
was exhibited by most reactive TPA2. TPA1, which was shown to be more inert in the substitution
reaction with n-acetyl methionine (NAM), exhibited less cytotoxicity activities by requiring
approximately two fold higher drug concentration than TPA2 and TPA3.
To evaluate the metabolic stability of TPA compounds, the cytotoxicity assays were also
performed after 24 h and 48 h incubation with fetal bovine serum (FBS). Serum is a liquid portion
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of blood and sulfur containing molecules responsible for the platinum drug inactivation are
abundant in serum (29). While cisplatin showed diminished cytotoxicity upon serum incubation
with an increase in IC50 value by 28 fold from 1.1 µM to 28.3 µM, TPA compounds retained their
cytotoxic activities significantly more effectively with less than 2 fold increase in IC50 (Figure 3.2).
Although the kinetic studies with NAM showed that TPA2 and TPA3 were more reactive than
TPA1, their stability in serum were not significantly different among these compounds. From these
results, TPA2 and TPA3 demonstrated superior cellular efficacy by demonstrating higher
cytotoxicity activities while demonstrating similar metabolic profiles.

Cellular Accumulation

Figure 3.4. Cellular accumulation of platinum compounds in A2780 cells. Cells were treated for 12 h
with 10 µM of platinum compounds following incubation with or without serum for 48 h. After the treatment
with each compound, cells were harvested and platinum uptake was measured on Varian ICP-MS. Error
bars indicate Mean ± S.E.M. from two independent experiments.
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Intracellular accumulation of platinum compound is one of the key factors contributing to
their cytotoxic activities. Decreased intracellular concentration is a known cause of cisplatin
resistance; thus, the intracellular concentration resulted from the treatment with TPA compounds
were assessed by using ICP-MS. Treatments of A2780 cells with 10 μM of cisplatin resulted in
intracellular platinum level of 45 attomole Pt Cell-1, while compounds generally demonstrated
higher cellular accumulation by resulting in 47 (TPA1), 119 (TPA2), and 89 (TPA3) attomole Pt
cell-1. TPA3 was speculated to show the highest accumulation due to presence of additional methyl
group on lactate, thereby contributing added hydrophobicity to the compound; however, the most
reactive TPA2 demonstrated highest intracellular platinum level among all compounds studied
(Figure 3.4)
Cellular accumulation was also measured after 48 h serum treatment since metabolic
inactivation is a known cause of the reduced accumulation (138,139). Intracellular platinum levels
of cisplatin decreased by 4.6 fold after serum incubation while TPA compounds demonstrated no
significant loss in intracellular platinum levels after the incubation (Figure 3.4). This is in
agreement with the metabolic stability of TPA compounds that were seen in cytotoxicity studies.
Interestingly, TPA2, the most reactive compound in this study, demonstrated highest intracellular
platinum concentration before and after the serum incubation. TPA2 demonstrated highest
cytotoxic activity and cellular accumulation while demonstrating similar stability profile to
metabolic inactivation in comparisons with other TPA compounds; therefore, a combination of
biophysical and biological assays indicate that TPA2 has the most promising pharmacological
properties amongst the compounds examined.

44

3.2 Cell Cycle Effects of TPA Compounds
3.2.1 Experimental
Analysis of Cell Cycle Distribution
A2780 cells were seeded in 10-cm tissue culture dishes at a density of 5 X 105 cells per dish. After
24 h, cells were treated with an equimolar dose of platinum compounds (10 µM) for 24 and 48 h.
Both attached and ﬂoating cells were harvested at the different time points. Cells were stained with
DNA intercalating fluorescent probe, propidium iodide, and analyzed using flow cytometry as
described previously (140,141).

3.2.2 Cell Cycle Effects

Figure 3.5. Effects of treatment with platinum compounds on cell cycle. A2780 cells were treated
with 10 µM of each platinum compounds for 48 h. Cells were then harvested, stained with propidium iodide,
and then analyzed using flow cytometry.

45

In a previous study reported by Fojo et al, cell cycle effects were examined with a series of
TPA compounds in KB-3.1, KBCP20 (cisplatin-resistant), and KBOX60 (oxaliplatin-resistant)
epidermoid carcinoma cells. The results showed that TPA compounds did not induce any
significant cell cycle effects (80). To confirm this result, cell cycle effects were evaluated in A2780
cells with TPA compounds synthesized in this chapter. After 48 h treatment, cisplatin disrupted
the cell cycle by slowing cell progression through S-phase in response to DNA damage (Figure
3.5). In contrast, a cytotoxic concentration of the TPA compounds did not significantly alter the
cell cycle, although a rise in sub-G1 indicating apoptotic activity was present upon treatment with
TPA compounds. The minimal influence in cell cycle may suggest that TPA compounds caused
cell death by a different mechanism than cisplatin, which may explain why TPA compounds
showed unaffected activity in cisplatin-resistant cells.

3.3 Possible Cellular Targets Other Than DNA

Figure 3.6. Bifunctional DNA crosslinks and DNA-protein cross-links induced by TPA. From ref (77).
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3.3.1 Ternary Topoisomerase I-DNA Interaction
Our results showing the minimal influence in cell cycle and the lack of perturbation in
DNA structure raise a question whether DNA is the only (or major target) of the TPA compounds
responsible for the cell death induced by the TPA compounds. While relatively few studies were
performed on the cellular effects of TPA, previous biochemical studies suggest that its cellular
pharmacology involves four distinct types of DNA lessions: monofunctional DNA adducts,
bifunctional DNA adducts, ternary DNA-DNA crosslinks, and ternary DNA-protein crosslinks
(9,78,97,142). Bifunctional intra-strand and inter-strand DNA adducts induced by platinum
compounds are known to cause significant DNA structural perturbation; however, trans isomers
are sterically restricted to form these adducts predominantly.
One interesting study revealed that treatment of MCF-7 (breast cancer cells) with trans[PtCl2(NH3)(tz)] and trans-[PtCl2(py)2]] resulted in a formation of DNA-topoisomerase I adduct
similar to that of camptothecin, a known topoisomerase I inhibitor (77). DNA topoisomerases are
essential enzymes that relieve the torsional strain by concerted breakage and rejoining of DNA
strands and have been recognized as a target for anticancer treatment (143). In contrast, this effect
was not evident with the cis isomer at the same concentrations. It is noteworthy to mention that
the formation of topoisomerase I-DNA upon treatment with trans-[PtCl2(NH3)(tz)] coincided with
the promotion of apoptosis while cisplatin treatment did not produce either topoisomerase I-DNA
complexes nor apoptosis (77). Although further details have to be studied, these findings suggest
that the unique platinum-DNA adduct structure induced by TPA compounds can lead to
significantly different cellular downstream effects such as protein recognition and apoptotic
pathways, which may provide an explanation of their unaffected activities in cisplatin-resistant
cells.
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3.3.2 Zinc-Finger Proteins
A zinc-finger is a small protein structural motif that is characterized by the coordination of
zinc ions with a combination of cysteine and histidine to stabilize the fold (144). Their functions
are diverse and they have become important cellular targets for anti-cancer and HIV treatments
(145,146). Platinum (II) compounds have a strong tendency to bind to sulfur or nitrogen containing
proteins, and zinc-finger motifs with cysteine and histidine have been investigated as possible
targets for the platinum compounds. The interaction of zinc-finger with trans-platinum compounds
was initially exemplified by trans-platinum mononucleobase compounds, where these compounds
interacted with the C-terminal finger of HIV NCp7 protein and resulted in zinc ejection from the
peptide, accompanied by loss of tertiary structure and its function (147).
A further zinc-finger target for TPA compounds was mentioned as zinc-finger Sp1 (148).
The human transcription factor Sp1 is a C2H2 zinc-finger protein that regulate gene expression by
binding to specific DNA sequences and they are known to have a pivotal role in various cellular
processes including tumorigenesis (149). trans-[PtCl2(NH3)(tz)] exhibited significant reactivity
to Sp1 while cisplatin did not show any detectable effect on Sp1. It is noteworthy to mention that
transplatin has shown much less affinity to Sp1, which suggests that thiazole ligand is a crucial
determinant for the high affinity that was shown with trans-[PtCl2(NH3)(tz)]. The platination of
Sp1 disrupts the secondary structure of the protein and interferes with the DNA-binding function
of Sp1 (148). This interference with zinc-finger motifs may down-regulate the expression of some
oncogenes and these results revealed a novel approach for the inhibition of Sp1, suggesting another
possible target responsible for the antitumor activity of TPA compounds.
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3.3.3 Telomerase
Telomerase was revealed as another possible target for TPA compounds in a study (150).
Telomeres are protective caps at the ends of human chromosomes, which shorten with each cell
division in normal cells whereas, in tumors, they are continuously lengthened by telomerase
enzymes. Telomerases are overexpressed in most of the cancers while they are present in very low
concentration in normal cells and it is recognized as a potential target for antitumor agents to inhibit
tumor cell proliferation (151). Upon treatment of MCF-7 cells with trans-[PtCl2(py)2], telomerase
activity was significantly inhibited in the first 24 h, while its cis isomer, cis-[PtCl2(py)2], did not
show any inhibition. The observation that trans-[PtCl2(py)2] induced a rapid decrease of
telomerase activity within 24 h suggests that trans-[PtCl2(py)2] interacts with existing telomerase
rather than preventing the telomerase synthesis (150). Although telomere length reduction seemed
not to be the main mechanism of the observed cell apoptosis induced by trans-[PtCl2(py)2], a rapid
and direct interaction with the existing pool of telomerase reveals another unique cellular feature
of TPA compounds.

3.3.4 Nuclear Protein Positive Cofactor PC4
An MS-based proteomic strategy utilizing DNA-conjugated gold nanoparticle probes
recently revealed that the human nuclear protein positive cofactor 4 (PC4) selectively binds to
cross-linked DNA by trans-[PtCl2(NH3)(tz)], implying that PC4 may play a role in cellular
response to DNA damage by trans-[PtCl2(NH3)(tz)] (152). This strategy was developed and
validated by a successful identification and quantification of HMGB1 (high mobility group protein
B1) upon cisplatin treatment, which is well known protein that interacts selectively with 1,2-crosslinked cisplatin-DNA adduct (152,153). The validated MS-based proteomic strategy was applied
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and identified the cellular proteins in response to DNA damage induced by trans-[PtCl2(NH3)(tz)].
Among the proteins identified, PC4 was most selective to the damaged DNA caused by trans[PtCl2(NH3)(tz)] (152). The multifunctional nuclear protein positive cofactor 4 (PC4) is involved
in various cellular processes including transcription, replication and chromatin organization; and
was also found to have a crucial role in the early response to DNA damage (154). Thus, the specific
interaction of DNA damaged by trans-[PtCl2(NH3)(tz)] and PC4 may be related to the unique
anticancer activity of trans-[PtCl2(NH3)(tz)] and further studies are deserved to understand the
unique cell death mechanism induced by TPA compounds.

3.4 Conclusion
The development of chemotherapeutic agents that can circumvent cisplatin resistance has
been a major ongoing strategy in platinum research. Previously, we have seen a promising
cytotoxic activity in cisplatin-resistant cells with TPA compounds. The major mechanism of
cisplatin resistance is known to be metabolic inactivation by sulfur molecules, reduced
accumulation, and enhanced Pt-DNA adduct recognition and repair. Thus, a combination of
systematic chemical (Section 2.3), biophysical, and biological properties were assessed to address
this issue with further optimized TPA compounds. From these results, we propose TPA2 as a lead
candidate for further development and examination to circumvent the existing cisplatin resistance,
where it demonstrated low micromolar cytotoxicity, enhanced metabolic stability, higher cellular
accumulation, and distinct cell cycle effects than cisplatin. From the DNA binding profile and cell
cycle effects induced by TPA compounds, it is tempting to speculate that other pharmacological
targets besides DNA may be responsible for the cell death caused by TPA; thereby, contribute to
their retained activity in cisplatin resistant cells. Further detailed mechanistic studies are deserved
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for a deeper understanding of the unique cytotoxic activity of TPA, which will provide a valuable
insight to the development of a clinically relevant TPA compound.

3.5 Contributions
Cytotoxicity and cell cycle effects were done by Vijay Menon.
Daniel E. Lee and Vijay Menon equally contributed to cellular accumulation study.
All of other work in this chapter was done by Daniel E. Lee.
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CHAPTER 4.

SYNTHESIS AND CHARACTERIZATION OF

POLYNUCLEAR PLATINUM COMPOUNDS

Figure 4.1. BBR3464 and its noncovalently binding analogues, AH44 and Triplatin NC

Despite its success demonstrated in pre-clinical and Phase I clinical studies, Phase II clinical
studies discouraged the usage of BBR3464 due to a rapid degradation of BBR3464 into inactive
metabolites (93,94). Its noncovalently binding analogues, AH44 and Triplatin NC, have overcome
the pharmacokinetic problems by binding with DNA solely through noncovalent electrostatic
interactions, which was accomplished by replacing chloride leaving group with inert ammine (NH3)
or “dangling amine” (NH2(CH2)6NH3). These highly charged platinum compounds introduced a
novel mode of DNA binding by interacting with negatively charged phosphate backbone of DNA
to cause DNA perturbation. With the distinct feature, they exhibited superior biological profile
including low micromolar cytotoxicity in tumor cells, high cellular accumulation and unaffected
cytotoxicity in cisplatin resistant and p53 mutant cells (Figure 4.2 and Table 4.1). Interestingly,
Triplatin NC (8+) exhibited higher cytotoxicity and cellular accumulation than AH44 (6+) in
various tumor cells by up to 20 fold (103). It is unclear why the higher charged compound with
dangling amine ligand exhibited these superior pharmacological properties and further
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investigation on structural-activity relationship are established in this chapter which is
accomplished by the synthesis of a novel series of noncovalently binding polynuclear platinum
compounds (PPC-NC) with varied number of platinum centers and the overall charge of the
compound.

Table 4.1. Cytotoxicity of cisplatin (c-DDP), BBR3464, AH44 (I), and Triplatin NC (II) in various tumor
cells. From ref (103).

Figure 4.2. Cellular accumulation of BBR3464, AH44 (I), and Triplatin NC (II). From ref (103).
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In efforts to establish a structure-activity relationship of PPC-NC, a series of dangling amine
PPC-NC with different (mono-, di-, tri-, tetra-) number of platinum centers, resulting in differences
in the overall charge and the length of the platinum compounds. It is important to note that AH44
(trinuclear, 6+) was studied with this series to directly compare between Diplatin NC (dinuclear,
6+) and Triplatin NC (trinuclear, 8+) to understand the biological consequences of the utilizing
different inert ligand (dangling amine vs ammine) to the PPC-NC.

Figure 4.3. Inhibition of heparinase I by cisplatin, PPC, and R9. From Ref (155).

Positive charge of PPC-NC is thought to be responsible for its higher cellular internalization,
where the mechanism involves binding to negatively charged heparan sulfate proteoglycans
(HSPG) (156). Recently, the strong binding of PPC-NC to HSPG showed inhibition of enzymatic
cleavage of the glycans by heparinase (155). Cisplatin did not inhibit cleavage, consistent with the
fact that it is not a substrate for HSPG-mediated internalization (Figure 4.3) (156). Heparinase is
an enzyme that is known to cleave HSPG and it is over-expressed in tumors and there is significant
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correlation between metastatic potential and heparinase activity (157,158). When HSPG are
degraded by the enzyme, it releases angiogenic and growth factors leading to cell migration,
growth, and angiogenesis (159,160,161); thus, the strong binding of PPC to HSPG to protect
against enzymatic cleavage opens a new approach to glycan targeting for antiangiogenic effects.
Yet, structure-activity relationship remains undefined. A series of PPC-NC synthesized in this
chapter can be used to further explore the antiangiogenic effects exhibited by PPC-NC in parallel
to their cytotoxic abilities.

Figure 4.4. Proposed target structures of PPC-NC (with dangling amine) and AH44 (with NH3).
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4.1 Synthetic Considerations
4.1.1 Synthetic Considerations of PPC Chloride Analogs (PPC-Cl)

Figure 4.5. 1H NMR spectra of different BBR3464 synthetic methods. A. 1H NMR spectrum of impure
BBR3464 resulted from previously published method (162,163). B. 1H NMR spectrum of pure BBR3464
obtained with new synthetic approach.

A critical step in the synthesis of the BBR3464 is the coupling of the central platinum unit
with the terminal platinum moieties (transplatin). In order to enable this conjugation, the amine
linkers of the central platinum unit have to be deprotonated. A previously utilized method (162,163)
to synthesize BBR3464 may result in an impurity involving protonated linker on the central
platinum (shown in Figure 4.5A, peak d). This prevents it from coupling the terminal platinum
unit to achieve the desired product and this impurity is extremely difficult to remove due to
similarities in solubility with the final product. To prevent this occurrence, an alternative synthetic
approach was developed to obtain the product more efficiently. The previous methods utilized an
equimolar of sodium hydroxide and transplatin to achieve the final product. One major challenge
in this synthetic approach was an occurrence of platinum reduction (Pt2+ → Pt0) in the presence of
the strong base, sodium hydroxide, which imbalances the stoichiometry of the reaction, resulting
in impurities. To prevent the platinum compounds from reducing, the non-nucleophilic base,
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DIPEA (N,N- diisopropylethylamine), was utilized. In addition, rather than utilizing exact
stoichiometric conditions, the new method utilizes slight excess of base and transplatin to ensure
the reaction to complete, where excess materials were removed by recrystallizing in
water/methanol once the reaction is complete.

4.1.2 Synthetic Considerations of PPC-NC

Figure 4.6. A comparison of 1) previous approach from ref (103) and 2) new synthetic approach to
synthesize Triplatin NC.
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Figure 4.7. New synthetic scheme of PPC-NC. a. 2 eq. AgNO3 then 2.2 eq. n-Boc-1,6-hexanediamine
in DMF, b. 0.1M HNO3. c. 1 eq. AgNO3 then 0.5 eq hexanediamine in DMF. d. 2.2 eq. DIPEA e. monoactivated transplatin, t-[Pt(NH3)2(Cl)(NO3)].

Previously published methods to synthesize Triplatin NC involve the coupling of
intermediate i, t-[PtCl(NH3)2(NH2(CH)6NHBOC)]NO3, to the central platinum moiety (Figure 4.6,
approach 1). The intermediate i can remain as an impurity if the exact stoichiometry is not achieved;
moreover, the solubility of i and the final product are very similar and they are extremely difficult
to separate. Due to those reasons, the synthesis of PPC-NC remained extremely challenging. To
overcome this difficulty, PPC-Cl were synthesized as intermediates, which was accomplished by
reacting mono-activated transplatin i to the deprotonated central platinum moiety. Then bocprotected dangling amine (N-Boc-1,6-hexanediamine) was attached to the PPC-Cl, followed by
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boc-deprotection to obtain the final product, where the residual ligand was removed by washing
the final product with methanol and acetone (Figure 4.6, approach 2). This novel synthetic strategy
can be applied to synthesize other compounds in the PPC-NC series as shown in Figure 4.7 and
this strategy successfully allowed the desired product to be obtained without further
separation/recrystallization.

The obtained compounds were characterized by

1

H NMR

spectroscopy (for the detection of residual ligands), 195Pt NMR spectroscopy (for the detection of
PPC-Cl), and elemental analysis (CHN) to ensure that the pure products were obtained.

4.2 Synthesis and Characterization of PPC-Cl

Figure 4.8. Structure of synthesized PPC-Cl.
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Starting Materials – All chemicals and solvents were purchased from common vendors. Dry
DMF was prepared by storing over 4 Å molecular sieves. Monoactivated transplatin was produced
by stirring transplatin with AgNO3 overnight in DMF at room temperature in the dark. AgCl was
removed by filtration.

Transplatin- Transplatin was prepared by using a method published previously (164).

1,1/t,t- 1,1/t,t was prepared using a methods published previously (46,165).
Yield- 83%

1

H NMR (D2O): δ 2.7ppm (2H, t), 1.7ppm (2H, m), 1.4 (2H, m). Elemental Anal

calc’d for C6H28Cl2N8O6Pt2- C 9.37, H 3.67, N 14.56. Obtained- 9.73, 3.36, N 14.19.

195

Pt NMR

(D2O): -2418 ppm

4.2.1 Synthesis of BBR3464 by New Approach
1 mmol of Monoplatin NC dissolved in DMF, 2.2 mmol of DIPEA was added. 2.2 mmol of monoactivated transplatin was added to the solution and the mixture was allow react for 2 days at
ambient temperature. The solution was evaporated to dryness under reduced pressure and was
dissolved in minimum amount of water. The reaction was filtered through syringe filter to remove
any unreacted starting material. The filtrate was evaporated to ~1mL under reduced pressure and
25mL of acetone was added to precipitate the product. The precipitant was collected through filter
and was washed with acetone.
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BBR3464- (Yield: 42%). 1H NMR (D2O): δ 2.7ppm (8H, m), 1.7(8H, m), 1.4 (8H, m). Elemental
Anal calc’d for C12H50Cl2N14O12Pt3- C 11.64, H 4.07, N 15.83. Obtained- C 11.66, H 3.52, N
15.31.

195

Pt NMR (D2O): -2425, -2679 ppm.

4.2.2 Synthesis of Tetraplatin-Cl
To 1 mmol of Diplatin NC (prepared as reported in section 4.3) dissolved in DMF, 2.2 mmol of
DIPEA was added. 2.2 mmol of mono-activated transplatin was added to the solution and the
mixture was allowed to react for 2 days at ambient temperature. The solution was evaporated to
dryness under reduced pressure and was dissolved in minimum amount of water. The reaction
was filtered through syringe filter to remove any unreacted starting material. The filtrate was
evaporated to ~1mL under reduced pressure and 25mL of acetone was added to precipitate the
product. The precipitant was collected through filter and was washed with acetone.

Tetraplatin- (Yield: 46%).

1

H NMR (D2O): δ 2.7ppm (12H, m), 1.7(12H, m), 1.4 (12H, m).

Elemental Anal calc’d for C18H72Cl2N20O18Pt4- C 12.66, H 4.25, N 16.40. Obtained- C 13.04, H
4.20, N 16.36.

195

Pt NMR (D2O): -2405, -2663 ppm.

4.3 Synthesis and Characterization of PPC-NC

4.3.1 Synthesis of Monoplatin NC
Monoplatin-Boc, trans-[Pt(NH3)2(NH2(CH2)6NHBOC)2](NO3)2
A mixture of trans-diamminedichloroplatinum (1 mmol) and AgNO3 (1.98 mmol) in dry DMF
was stirred overnight protected from light. The following morning, formed AgCl was filtered off.
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A solution of the mono-BOC-protected hexanediamine (2.2 mmol) in dry DMF was added to the
filtrate. The mixture was stirred for 3 days protected from light at ambient temperature. The solvent
was then removed under reduced pressure. The residue was then dissolved in 100 ml of water at
50 °C and filtered through a membrane filter to remove any reduced silver and platinum. The
filtrate was evaporated to dryness and the obtained white solid was suspended and washed with
acetone/methanol to remove any unreacted starting material. Yield- 74.3%.

1

H NMR(D2O): δ

3.05(t, 4H), 2.65(t, 4H), 1.60 (m, 8H), 1.4 (m, 26H).

Monoplatin NC, trans-[Pt(NH3)2(NH2(CH2)6NH3)2](NO3)4
1 mmol of the Monoplatin-Boc was suspended in a mixture of 25 ml 0.5 M HNO3 and stirred for
2 days at room temperature. The mixture was filtered through celite to remove any unreacted
starting materials and reduced silver/platinum. The volume of the filtrate was reduced to almost
dryness and acetone was added to force the precipitation of the product. The formed precipitate
was filtered off then washed with acetone. Yield- 92.3%. 1H NMR(D2O): δ 3.01(t, 4H), 2.65(t,
4H), 1.60 (m, 8H), 1.4 (m, 8H).

Pt NMR (D2O): -2653 ppm. Anal. Calc’d for C12H40N10O12Pt:
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C 20.25, H 5.67, N 19.68. Found: C 20.21, H 5.60, N 19.62

4.3.2 Synthesis of Diplatin NC, Triplatin NC and Tetraplatin NC
Diplatin NC-Boc, Triplatin NC-Boc, and Tetraplatin NC-Boc
To 1 mmol of PPC-Cl (Diplatin, Triplatin, Tetraplatin) dissolved in DMF, 1.98 equivalents of
silver nitrate was added. The reaction was allowed to stir for 16 h protected from light. Next day,
AgCl formed during the reaction was filtered through celite. To the filtrate, 2.2 equivalents of n-
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boc-1,6-hexanediamine was added. The reaction was allowed to stir for 2 days at room temperature.
The solution was evaporated to dryness under reduced pressure. Then 100 ml of water was then
heated to 60 ºC to dissolve the product. Dissolved product was filtered through celite to remove
any reduced platinum and silver. The filtrate was evaporated to dryness and acetone was added to
precipitate the product. The precipitant was collected through filter and washed with acetone.

Diplatin NC-BOC- Yield: 64%. 1H NMR(D2O): δ 3.05(t, 4H), 2.65(t, 8H), 1.60 (m, 12H), 1.4
(m, 30H).
Triplatin NC-BOC- Yield: 58%. 1H NMR(D2O): δ 3.02(t, 4H), 2.63(t, 12H), 1.62 (m, 16H), 1.4
(m, 34H).
Tetraplatin NC-BOC- Yield: 52%. 1H NMR(D2O): δ 3.05(t, 4H), 2.64(t, 16H), 1.60 (m, 20H),
1.4 (m, 38H).

Diplatin NC, Triplatin NC, and Tetraplatin NC
0.1 mmol of complex Di-, Tri, and Tetraplatin NC-Boc were suspended in 25 ml aqueous 0.1 M
HNO3 and stirred for 4 days at 50 °C. At the end of the reaction the suspension had turned into a
clear almost colorless solution. 1H NMR was utilized to confirm the completion of the bocdeprotection. The solution was filtered through celite to remove any unreacted starting material.
The filtrate was evaporated to almost dryness and acetone was added to force the precipitation of
the product. The residue was collected through filter and washed with methanol and acetone. If
further purification was necessary, the crude product was recrystallized in water.
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Figure 4.9. 1H NMR spectra of A) Monoplatin NC, B) Diplatin NC, C) Triplatin NC, D) Tetraplatin NC.
A, C, D were obtained by 300MHz NMR while B was obtained by 600MHz NMR.
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Diplatin NC- Yield- 93%. 1H NMR (D2O): δ 3.0 (t, 4H), 2.65 (m, 8H), 1.65 (m, 12H), 1.37 (m,
12H). Elemental Anal calc’d for C18H62N16O18Pt2- C 18.31, H 5.29, N 18.98. Obtained- C 18.51,
H 5.27, N 18.47.

195

Pt NMR (D2O): -2651 ppm

Triplatin NC- Yield- 84%. 1H NMR (D2O): δ 3.0 (t, 4H), 2.65 (m, 12H), 1.65 (m, 16H), 1.37 (m,
16H). Elemental Anal calc’d for C24H84N22O24Pt3- C 17.47, H 5.13, N 18.67. Obtained- C 17.27,
H 5.02, N 18.21.

195

Pt NMR (D2O): -2652 ppm

Tetraplatin NC- Yield- 84%. 1H NMR (D2O): δ 3.0 (t, 4H), 2.65 (m, 16H), 1.65 (m, 20H), 1.37
(m, 20H). Elemental Anal calc’d for C30H106N28O30Pt4- C 17.00, H 5.04, N 18.50. Obtained- C
16.58, H 4.62, N 17.98.

195

Pt NMR (D2O): -2652 ppm

4.4 Contributions
All of the work in this chapter was solely done by Daniel E. Lee.
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CHAPTER 5.

DNA BINDING PROFILES AND CELLULAR EFFECTS
OF POLYNUCLEAR PLATINUM COMPOUNDS

Figure 5.1. Structure of PPC-NC studied in this chapter.

Noncovalently binding polynuclear platinum compounds (PPC-NC) introduced a new mode
of DNA binding by interacting with negatively charged phosphate backbone of DNA. Furthermore,
PPC-NC circumvented the pharmacokinetics of covalently binding platinum compounds by
demonstrating inertness to metabolic inactivation by sulfur nucleophiles, while demonstrating low
micromolar cytotoxicity and high cellular accumulation. To further investigate and establish the
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structure-activity relationship (SAR) of PPC-NC, various PPC-NC with different charges and
numbers of platinum centers were synthesized and characterized, as described in the previous
chapter. In this chapter, a combination of biophysical and biological assays were utilized to
investigate the effects of structural variation on DNA binding, cytotoxicity, and cellular
accumulation. The suggested cellular entry mechanism of PPC-NC are also reported in this chapter.

5.1 Determination of Platinum Compound-DNA Interactions
5.1.1 Background

Figure 5.2. Hydrogen Bonds between Triplatin NC and DNA. From Ref (98). (A) View perpendicular to
the helical axis. (B) View along the helical axis. Atoms are colored by type with carbon (DNA), green; carbon
(Triplatin NC) gray; nitrogen, blue; oxygen, red; platinum, yellow.

Phosphate Clamp
Replacement of the labile chloride leaving groups with kinetically inert NH3 ligands
introduced an entirely novel class of noncovalent polynuclear platinum compounds (PPC-NC),
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where interactions with DNA are through electrostatic and hydrogen-bonding noncovalent
interactions exclusively (101,166). Crystallographic characterization of DNA with these inert
cationic compounds revealed that PPC-NCs do not intercalate nor do they bind in the major or
minor groove; however, they interact with negatively-charged phosphate oxygen atoms and thus
associates with the backbone of DNA with high affinity (Figure 5.2) (101,102). This unique
binding, “phosphate clamps”, introduced a new DNA binding mode mimicking that of
polyarginine, extending the diversity of binding possibilities of platinum chemotherapeutics
(Figure 5.3).

Figure 5.3. Arginine fork (left) and phosphate clamp (right).

DNA Condensing Effects of PPC-NC
DNA has high anionic character due to the negatively charged phosphate backbone. Due
to this reason, agents that bind through non-covalent interactions are often cationic. Recently,
studies on DNA condensation have received additional attention with considerable potential
interest for gene therapy, where the mechanistic details of DNA packing are essential for proper
function in the gene regulation processes in living systems (167,168). Moreover, it was found that
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the cytotoxicity of synthetic polyamine analogues is generally correlated to their ability to
condense DNA (169).

Figure 5.4. Pictorial representation showing the mechanism of DNA condensation by cationic
molecules. Modified from ref (170).
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Condensation of DNA can be induced by different agents: polyamines, multivalent cations,
histones, and positively charged polypeptides (171,172,173,174,175,176). Binding of DNA with
cationic molecules can be generally described as a three-stage process: initial binding, DNA
condensation, and precipitation. Figure 5.4 shows a general schematic of this occurrence by
cationic molecules (170). At a low concentration of a cationic molecule, DNA repels each other
due to electrostatic repulsion caused by negatively charged phosphate backbone. As the
concentration of the cationic molecule increases, the charge on the phosphate backbone is
neutralized and electrostatic repulsion is reduced. Then interhelical cross-links occur which, in
turn, cause the condensation of DNA (170). Any further increase in the concentration of cationic
molecules would result in the neutralization of negative charged of the DNA, which ultimately
leads to the precipitation of DNA-cation adduct.

Figure 5.5. Representative AFM images of linearized negatively supercoiled plasmid DNA, pSP73,
in the presence of PPC-NC. From Ref (177).

Recently, the DNA condensing effect was examined with PPC-NC by Brabec et al through
biochemical and biophysical methods including visualization by atomic force microscopy as
shown in Figure 5.5 (177). PPC-NCs were found to condense DNA at ~20 fold lower
concentration than spermine, a known DNA condensing cationic molecule. Although biological
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consequences of DNA condensation induced by PPC-NC is still unclear, it shows another unique
feature of PPC-NC resulted, which may be closely related to their unique cytotoxic activities.
The formation of DNA-Pt adducts and perturbation of DNA structure are crucial
determinants of the cytotoxicity profile of the compounds. In this section, biophysical studies were
utilized to measure the DNA binding affinity and to further observe the condensing effects induced
by a series of PPC-NC with varied structures: Monoplatin NC (4+), Diplatin NC (6+), Triplatin
NC (8+), Tetraplatin NC (10+), and AH44 (6+) (Figure 5.1).

5.1.2 Experimental Conditions

PPC-NC were synthesized as reported in Chapter 4. AH44 was synthesized by Ralph Kipping. All
other chemicals were obtained from common chemical vendors.

Isothermal Titration Calorimetry
The experiments were carried out at 25°C using a Microcal VP-ITC (Microcal, Northampton, MA).
Calf thymus DNA and drug solutions each were prepared in 10 mM NaClO4 with pH 7.0 with a
concentration of 500 μM. All samples were degassed prior to analysis. The platinum solution was
titrated into the DNA mixture by making 38 injections of 7.5 μL every 300 sec at a stirring rate of
310 rpm. The actual heats of binding were obtained after subtracting the heats of dilution for the
injections of platinum drug into buffer. Origin 7.0 software was used to fit the corrected data and
determine the binding affinity (K), changes in enthalpy (ΔH), binding stoichiometry (n), and
changes in entropy (ΔS). From these initial measurements, the Gibbs free energy (ΔG) was
determined by using Gibbs energy isotherm equation. The molar ratio where precipitation occurs
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was also obtained by analyzing the curve, which was verified by visual inspection of the sample
after the ITC analysis. The experiments were performed in duplicate.

Circular Dichroism
Calf thymus DNA was incubated with the platinum compounds at 37°C in the dark for 1h at
following Ri (platinum compound/DNA ratio) values: 0, 0.025, 0.05, 0.075, and 0.1. CD spectra
were recorded at room temperature using a Jasco J600 Spectropolarimeter and a 10 mm sub-micro
cuvette. The buffer background was subtracted from the obtained spectra. Concentration of DNA
was 100 μM bases in a perchlorate buffer (10 mM NaClO4, pH 7.0).

5.1.3 Results and Discussion

Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) is a physical technique used to determine the
thermodynamic parameters of interactions in solution and has become a widely used method in
recent years to study the binding of small molecules to large biomolecules of interest. By using
this technique, binding affinity (K), changes in enthalpy (∆H), and binding stoichiometry (n) can
be measured, where changes in Gibbs energy (∆G) and changes in entropy (∆S) can be also
obtained by using the following equation (Eq. 1).

∆G = -RTlnK = ∆H - T∆S
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Isothermal titration calorimetry (ITC) is a useful method to explore the interaction between
DNA and cationic ligands, where ITC is the only technique that can simultaneously determine all
binding parameters in a single experiment without requiring modification of binding target.
(178,179). By titrating a solution of cationic molecules into a DNA solution, the thermodynamic
parameters such as changes in enthalpy, entropy, and free energy can be obtained by fitting the
best ITC curve. Nevertheless, this can be a useful technique to observe a conformational change
in DNA, where the phosphate backbone is interacting with PPC-NC thereby causing the DNA to
compact, ultimately inducing DNA condensation. Based on the results with previously studied
PPC, cationic PPC exhibited strong DNA binding properties through noncovalent interactions
inducing DNA condensation at much lower concentrations than naturally occurring cationic
ligands such as spermine and spermidine (177,180). To explore this unique feature and strong
DNA-binding affinity exhibited by PPC-NC in more detail, PPC-NC with different length, charge,
and number of platinum centers were studied by ITC.
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Figure 5.6. ITC profile for the binding of Triplatin NC with CT-DNA. The isotherm is divided into 3 stages:
1) 1st binding stage 2) condensation 3) precipitation.

Figure 5.7. ITC profiles for the binding of PPC-NC to CT-DNA. A) Monoplatin NC(4+), B) Diplatin NC(6+),
C) Triplatin NC(8+), D) Tetraplatin NC(10+), E) AH44(6+).
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Table 5.1. Best fit parameters for titration of CT-DNA with platinum compounds. These values were
obtained by plotting the best fit on the initial binding stage of the compounds with CT-DNA by using Origin
7.0.

a)

From ref (181). N.R= Not reported.

In summary, the binding of the platinum compounds with DNA is a thermodynamically
favorable event (∆G = negative) where it is driven entropically opposed by unfavorable enthalpy
change and favorable entropy change, which is in an agreement with the most of noncovalently
binding compounds (Table 5.1). It is known that binding of cations to phosphates on the
polynucleotide backbone of DNA is entropically driven by the release of counter-ions and water
and opposed by the binding enthalpy (182). The Gibbs free energy (∆G) values were all in the
similar range for the compounds studied, where these values were generally lower than the
naturally occurring cationic spermidine indicating that these events were more favorable for the
PPC-NC.
The titration curve with CT-DNA consists of three endothermic binding stages (initial
binding, condensation, and precipitation), which were labeled and shown in Figure 5.6. The
isotherm of the compounds allows for determination of the molar ratios of different binding stages
through the visualization of the isotherms. In general, the occurrence of DNA condensation and
precipitation occurred faster for the higher charged compounds. The binding stoichiometry (N) for
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the initial stage showed a similar trend, where this value generally decreased as the charges of the
PPC-NC increased (Table 5.1); however, the condensation process started faster with AH44 (6+)
compared to Diplatin NC (6+). Nevertheless, the stoichiometry of AH44 was higher than Diplatin
NC although they were both 6+ charged. The DNA binding profile of AH44 was similar to that of
Triplatin NC (8+), which may suggest that that the number of platinum centers are more crucial in
determining DNA binding affinity and the DNA condensing effects of the compounds than the
charge state.
Due to the complexity of DNA and the occurrence of multiple events with cationic
molecules, many values obtained from these isotherms are generally rough estimates, which
heavily depend on the best curve fitting method. From literature, utilizing different plotting
techniques has resulted in different binding constant values which differ up to 100 fold on an
isotherm of cationic molecules interacting with DNA (183). This discrepancy will influence the
the entropy (∆S) and Gibbs free energy (∆G) values obtained from the isotherms, since these values
were obtained by using an equation involving the binding constant (K); Therefore, the values
obtained from ITC possess a certain degree of inaccuracy and are not further discussed.

Circular Dichroism
Circular dichroism (CD) measures a difference in absorbance by a substance of right- and
left- handed circularly polarized light (184,185). An increased relative absorption of left-handed
polarized (LPL) light results in a positive band in an absorption spectrum while an increased
relative absorption of right-handed polarized light (RPL) will result in a negative band (Eq 2).

Circular dichroism = ΔA(λ) = A(λ)LPL ‐ A(λ)RPL, λ= wavelength

78

CD is an excellent method for rapidly evaluating the secondary and tertiary structure, and
binding properties of biologically-relevant molecules like proteins and DNA at low concentrations.
The typical CD spectrum of a DNA sample is observed in the ultraviolet region between 300 nm
and 180 nm, where nucleobases absorb light (186). Changes of bands in the CD spectra allow for
distinction of different forms of DNA (B-form, A-form, and Z-form) and monitoring of
conformational polymorphism of DNA and DNA-drug complexes (187,188).

Figure 5.8. CD spectra of 3 mM of CT-DNA at various concentration of hexamminecobalt (III). (1) Ri
= 0; (2) Ri =0.098;(3) Ri =0.197; (4) Ri =0.216; (5) Ri =0.256; (6) Ri =0.275; (7) Ri =0.295; (8) Ri =0.314; (9)
Ri =0.334; (10) Ri =0.353. From ref (189).

Change in the secondary structure of DNA through interactions with PPC-NC were
observed by CD to confirm the data obtained from ITC and to further investigate (190). Previously,
Bloomfield et al have investigated the interaction of heamminecobalt(III), Co(NH3)63+, with calf
thymus DNA (CT-DNA), which revealed two stages of the interaction: binding prior to
condensation (Figure 5.8; 1-5) and binding during condensation (Figure 5.8; 6-10) (189). From
the ITC study, DNA condensation occurred faster with PPC-NC with higher number of platinum
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centers and this trend can be confirmed and further explored by utilizing CD to establish the effect
of PPC-NCs structural variation on the DNA binding and DNA condensing effects.

Figure 5.9. CD spectra of CT-DNA treated with various amounts of platinum compounds. 100 µM
of CT-DNA prepared in 10 mM NaClO4 were treated with platinum compounds at different R i (DNA to
drug ratio) and incubated for 1 h.
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Figure 5.10. Changes of the ellipticity at 210 nm (top) and 274 nm (bottom) upon treatment with
different Ri (DNA to platinum compounds).

81

Figure 5.11. Comparison of the compounds at Ri= 0.05 (Top) and Ri=0.1 (Bottom).
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Figure 5.9 shows the outcome of the CD experiments of the PPC-NC with CT-DNA.
Increase in the number of platinum center of PPC-NC correlated with their ability to induce
conformational changes of CT-DNA, whereas Tetraplatin NC induced the most structural
perturbation while Monoplatin NC has induced the least. This effect can be measured by observing
the positive band at 274 nm and the negative band at 210 nm of CT-DNA. The positive band at
274 nm initially decreased and the negative band at 210 nm increased as the concentration of the
compound increased. At higher concentrations, a complete inversion of the band occurred at 274
nm which was observed with Triplatin NC, Tetraplatin NC, and AH44 which may be indicative of
DNA condensation. This event occurred at a lower Ri (drug to nucleotide ratio) with Tetraplatin
NC compared to the other compounds, indicating a greater condensing effect and DNA binding
affinity due to the higher charge and length. The conformational changes occurring at 210 nm and
274 nm were graphed in Figure 5.10, where it showed a general trend that PPC-NC with a higher
number of platinum centers have induced greater conformational changes of CT-DNA.

Figure 5.12. Structures of Diplatin NC, AH44, and Triplatin NC
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It is also interesting to compare and contrast between Diplatin NC, Triplatin NC and AH44.
Diplatin NC and Triplatin NC utilize dangling amine inert ligand while AH44 utilizes ammine
inert ligand. Although Diplatin NC and AH44 have the same overall charge (6+), they showed
different DNA binding profiles. They exhibited similar degree of DNA conformational change up
to a ratio of 0.05; however, at a ratio of 0.075 and above, AH44 induced dramatic changes in the
CD signal indicating DNA condensation, similar to that of Triplatin NC, which was not observed
with Diplatin-NC (Figure 5.11). These results are in good agreement with those obtained from
ITC, where the overall DNA binding profile of AH44 was similar to that of Triplatin NC, while
Diplatin NC induced less DNA structural perturbation. These results suggest that the number of
platinum centers in PPC-NC are more crucial determinant in terms of DNA binding than the charge
state of the PPC-NC.

5.2 Biological Activities of Polynuclear NC Compounds

5.2.1 Experimental
Cell Culture
HCT116 cells were obtained from the American Type Culture Collection. HCT116 cells were
grown in monolayer culture in RPMI 1640 (Invitrogen, Grand Island, NY, USA; Cat# 11875-093)
supplemented with 10% fetal bovine serum (Quality Biologicals, Gaithersburg, MD, USA; Cat#
110-001-101US) and 100 U/mL penicillin and 100 mg/mL streptomycin (Invitrogen, Grand Island,
NY, USA; Cat# 15140), at 37 °C in a 5% CO2 incubator.
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Cellular Accumulation
HCT116 cells were seeded in 100 mm dishes (2 × 106 cells/plate). After 24 h, cells were treated
with 10 µM of the platinum compounds. After 3 h and 6 h, cells were harvested and washed twice
with PBS. To digest samples, 1 mL of concentrated HNO3 was added to the pellet and left to digest
for three days. 2 mL of water were then added to dilute the samples and the solutions were filtered
through a 0.45 μGHP filter, and analyzed on inductively coupled plasma mass spectrometry (ICPMS) to determine the platinum concentration. Error bars indicate Mean ± S.D. from two
independent experiments. Standards and blanks were prepared the same as the samples.

Growth Inhibition Assay
HCT116 cells were seeded in 96-well plates (5 × 103 cells/well) in 100 μL of RPMi media with
10 % v/v fetal bovine serum, 100 U/ml penicillin, and 100 μg/mL streptomycin. They were allowed
to attach overnight. After 24 h, cells were treated with various concentrations (0.78 – 50 μM) of
platinum drugs in sets containing 4 replicates. After drug exposure for 24 hours, 1 mM MTT (3(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma), was added to each well
and incubated for 4 hours at 37 °C. The MTT reagent was removed, and 100 μL of DMSO was
added to each well. Spectrophotometric readings were determined at 492 nm using a microplate
reader (Bio-Tek instruments).
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5.2.2 Cellular Accumulation of PPC-NC in HC116 Cells

Figure 5.13. Cellular accumulation (attomole of Pt/cell) of PPC-NC and AH44 in HCT116 cells.

Previously, Triplatin NC (8+) and AH44 (6+) showed higher cellular accumulation than
its covalently binding congener BBR3464 (4+) and cisplatin. To extend the spectrum of the
structure-activity relationship exhibited by highly-charged cationic PPC, cellular accumulation of
Mono-, Di-, Tri-, and Tetraplatin NC were assessed in HCT116 (human colon carcinoma) cells
after 3 h and 6 h of drug treatment and they were quantified by ICP-MS. Figure 5.13 shows the
pattern that platinum levels (attomole of Pt / Cell) were highest with Tetraplatin NC while
Monoplatin NC was lowest as expected; however, Tetraplatin NC has four platinum centers per
molecule while Monoplatin NC has one platinum center per molecule. To normalize this, the
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values were divided by the number of the platinum centers (attomole of drug/ cell) as shown in
Figure 5.14.

Figure 5.14. Cellular accumulation (attomole of drug/cell) of PPC-NC and AH44 in HCT116 cells.

When expressed in attomole drug per cell, Monoplatin NC (4+) displayed the highest
amount of drug level in the cells. Similar amount of drug accumulation was observed with Di-,
Tri-, and Tetraplatin NC, while AH44 has shown significantly lower accumulation than those with
dangling amine (H2N(CH2)6NH3). This may contradict with our previous conclusion, where it was
initially speculated that the higher charge was responsible for the higher accumulation in cells and
this correlation was established with BBR3464 (4+), AH44 (6+), and Triplatin NC (8+) (103,156);
however, this result suggests that the choice of the inert ligands are a more crucial determinant
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contributing to cellular accumulation of PPC-NC, whereas PPC-NC with dangling amine linker
(Mono-, Di-, Tri-, Tetraplatin NC) showed higher uptake than that of ammine (AH44).

5.2.3 Growth Inhibition Effects of PPC-NC

Figure 5.15. Cytotoxicity of PPC-NC determined by MTT assay.

Table 5.2. Cytotoxicity of PPC- NC compounds determined by MTT assay in HCT116 cells.
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Cytotoxicity of PPC-NC compounds in HCT116 cells was assessed by MTT assay. The
results were shown in Table 5.2. Tetraplatin NC was found to be most cytotoxic by exhibiting an
IC50 value of 2 µM, whereas Monoplatin NC did not induce significant cytotoxic activities (>50
µM). This result established a trend that PPC-NC with higher charge and number of platinum
centers exhibit higher cytotoxic activities. From the biophysical and cellular accumulation studies,
AH44 showed superior DNA binding profile (Section 5.1) while Diplatin NC resulted in higher
cellular accumulation (Section 5.2). Despite the differences in the DNA binding profile and
cellular accumulation profiles, they exhibited similar cytotoxic activities in HCT116 cells.
Cytotoxicity exhibited by platinum compounds can be correlated by the frequency and nature of
DNA adducts and the efficiency of cellular platinum accumulation, and this result is thought to be
a consequence of combination of these properties of each platinum compound. Overall, we
propose Tetraplatin NC as a lead compound, where it demonstrated highest DNA binding affinity
and cellular accumulation, which ultimately resulted in highest cytotoxicity.

5.3 Interactions of PPC and Heparan Sulfate
One distinct cellular profiles of PPC-NC is that the cellular uptake is significantly enhanced
compared to cisplatin despite of their charge states. The cellular uptake mechanism of neutrally
charged cisplatin is known to be mediated by active transporters (e.g. CTR1) or by passive
diffusion (139,191). The exact mechanisms of cationic PPC enter cells has not been established,
but studies suggest the uptake is mediated by heparan sulfate proteoglycans (HSPG) (156).
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Figure 5.16. Pathway for the cationic PTDs (R9) into cells. From ref (192)
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Figure 5.17. Major and minor repeating disaccharide sequences of heparin. From ref (193).

HSPG, a type of glycosaminoglycan (GAG), are glycoproteins with the common
characteristic of containing one or more covalently attached heparan sulfate chains (194,195,193).
GAGs, including heparan sulfate (HS), heparin, and chondroitin sulfate (CS) are composed of
repeating disaccharide units differing in number and position of sulfate groups (196). HSPG are
known to mediate the cellular internalization of cationic protein transduction domains (PTDs) and
polyamines (192,197,198). Figure 5.16 shows the pathways of cellular internalization of R9, the
most efficacious known PTD. There are four steps in the process: (1) binding to cell surface HS,
(2) uptake by endocytosis, (3) release upon HS degradation, and (4) leakage from endocytic
vesicles (192). The uptake pathway cationic PPC-NC is suggested to be similar and this was
confirmed by cellular accumulation of PPC-NC in wt CHO (chinese hamster ovary), mutant CHOpgsD-677 (lacking HS), and CHO-475 (lacking HS/CS) cells (Figure 5.18). The cellular
accumulation of PPC-NC in all three CHO cells showed GAG dependency, which suggests that
HSPG-mediated interactions are crucial for the cellular internalization of PPC-NC (156).
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Figure 5.18. GAG dependent cellular accumulation of PPC-NC. 2 x 106 cells were treated with 10 µM
platinum compounds. After 1 h, cells were harvested and washed with PBS buffer. After acid digestion,
platinum analysis was performed on ICP-OES. From ref (156).

The interaction of PPC-NC and DNA revealed that PPC-NC binds to negatively charged
phosphate backbone of DNA similar to that of cationic arginine, where this new mode of binding
is described as “phosphate clamp”. Similarly, the interaction of PPC-NC and HS is speculated to
be a consequence of positively charged PPC-NC and negatively charged sulfates on HS, where
this “sulfate clamp” motif is suggested and shown in Figure 5.19.
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Figure 5.19. Arginine fork, phosphate clamp, and sulfate clamp.

5.3.1 Cellular Accumulation of PPC-NC in HSPG deficient Cells

Experimental Conditions
CHO wt and CHO-745 cells were seeded in 100 mm dishes (2 × 106 cells/plate). After 24 h, cells
were treated with 10 µM of the platinum compounds. After 3 h, cells were harvested and washed
twice with PBS. To digest samples, 1 mL of concentrated HNO3 was added to the pellet and left
to digest for three days. 2 mL of water were then added to dilute the samples and the solutions
were filtered through a 0.45 μGHP filter, and analyzed on ICP-MS to determine the platinum
concentration. Error bars indicate Mean ± S.D. from two independent experiments. Standards and
blanks were prepared the same as the samples.
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Results

Figure 5.20. Cellular accumulation of PPC-NC compounds in CHO wt and CHO-745 HSPG deficient
cells. Cells were treated with 10 µM of platinum compounds for 3 h.

The intracellular platinum concentration of PPC-NC in CHO wt and CHO-745 (deficient
in HS and CS) was measured to confirm the dependency of PPC-NC compounds on HSPG status
of the CHO cells. The result confirmed that cellular internalization of PPC-NC heavily depends
on the status of HSPG by showing significantly lower cellular accumulation in HSPG deficient
cells, while cisplatin did not show any dependency on HSPG status. Previously, it was suggested
that the HSPG-mediated internalization correlates with the charge state of the compounds (156);
however, as shown in Figure 5.20, the cellular accumulation of PPC-NC in CHO wt and CHO-745
was dependent on the choice of the inert ligand rather than the charge of the compound, which
confirmed the result of cellular accumulation study in HCT116 cells (Section 5.2).
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5.3.2 Interaction with D-glucosamine-3-sulfate by HSQC [1H,

15 N]

Spectroscopy and

ITC

Figure 5.21. Structure of 15N labelled BBR3464.

Experimental Conditions
Starting Materials
D-glucosamine-3-sulfate was purchased from Sigma Aldrich. 15N-labelled BBR3464 was prepared
with 15N labelled ammine and 1,6-hexanediamine by using a method described in Section 4.2.1.

2D [1H, 15N] HSQC NMR Spectroscopy
The NMR spectra were recorded on a Bruker AVANCE 600 MHz spectrometer (1H, 599.92 MHz;
15

N, 60.79 MHz). The 1H spectra were internally referenced to 1,4 dioxane (δ= 3.767 ppm), and

the 15N chemical shifts were externally referenced to 15NH4Cl (1.0 M in 1.0 M HCl in 95% H2O/5%
D2O) at δ(15N)=0.0 ppm. The 1H NMR spectra were acquired with water suppression using the
WATERGATE pulse sequence (199). The 2D [1H,

15

N] HSQC NMR spectra (decoupled by

irradiation with the GARP-1 sequence during acquisition) optimized for 1J(15N,1H)=72 Hz were
recorded using the standard Bruker phase sensitive HSQC pulse sequence (200). One-dimensional
1

H spectra were recorded with 32 transients, a spectral width of 12 kHz, and a relaxation delay of

1.5 s. For the 2D [1H, 15N] HSQC NMR spectra, 8 transients were collected for 128 increments of
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t1 with an acquisition time 0.152 s and spectral widths of 2 kHz in ƒ2 (1H) and 1.8 kHz in ƒ 1 (15N).
The spectra were processed using Gaussian weighting functions in both dimensions.

Isothermal Titration Calorimetry
Procedure was followed as described in Section 5.1.2.

Results

Figure 5.22. Structure of glucosamine-3-sulfate.

Heparin sulfate is extremely difficult to analyze and quantify since they are polydiverse
and microheterogeneous polymers where the molecular weight ranges from 3 kDa to 30 kDa (201).
To overcome this obstacle,

15

N labelled PPC was synthesized to allow for the detection and

quantification of the interaction by HSQC [1H, 15N] NMR spectroscopy. Initially, the interaction
of PPC-NC and heparin sulfate was attempted; however, the PPC-NC and heparin sulfate adducts
could not be characterized due to an immediate precipitation of the final product. A less complex
molecule, glucosamine-3-sulfate (G3S), a monosaccharide unit of HS, was chosen in this study as
a probe to observe an interaction between PPC-NC and heparin sulfate. The interaction of G3S
and BBR3464 was observed up to 72 h; however, no changes were observed in the spectra as
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shown in Figure 5.23, suggesting that the interaction between sulfated monosaccharide G3S was
not strong enough to be detected.

Figure 5.23. HSQC [1H, 15N] of 2 mM of BBR3464 with 8 mM glucosamine-3-sulfate (G3S). A) BBR3464
without G3S. B) BBR3464 with G3S after 72 h. NH 3 region: (I) PtN3Cl, (II) PtN4. NH2 region: (III) PtN4.
PtN3Cl in NH2 region is not shown in this spectra since it overlaps with the water peak.

To confirm this result, isothermal titration calorimetry was utilized to detect interactions
of G3S with BBR3464 and Triplatin NC since it can detect the interaction between two molecules
by measuring the change of heat released or absorbed with high sensitivity. Based on the isotherm,
it can be concluded that the interaction of PPC and G3S was not significant enough to detect
(Figure 5.24). This may suggest that individual noncovalent bond between monosaccharide and
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PPC are individually weak; but multiple noncovalent interactions allow to form strong adduct
between HS and PPC.

Figure 5.24. Isothermal Titration Calorimetry of BBR3464 and G3S.

5.3.3 Colorimetric Assay to Quantify PPC-NC and Heparin Sulfate Interaction

Figure 5.25. Structure of methylene blue (MB) dye.
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A monosaccharide unit of heparin sulfate, G3S, did not show any interaction with PPCNC; therefore, there was a need to develop a method to detect between PPC-NC and heparin sulfate.
To accomplish this, a colorimetric assay using methylene blue (MB) was developed. MB is a
cationic dye which is known to interact with negatively-charged functional groups on
polysaccharides through electrostatic interactions. This interaction causes a shift in the absorption
spectrum of MB, which can be used for the detection and quantification of heparin (202). Cationic
PPC-NC binds to heparin strongly and the pre-treatment PPC-NC prevented the binding of MB to
heparin which allowed the quantification of PPC-NC and heparin adduct.

Experimental
Heparin sulfate was purchased from Sigma Aldrich. Proteoglycan detection kit including
methylene blue dye was purchased from Astarte Biologics (Cat #8000).

Preparation of standards and samples
Stock standard solutions were prepared in deionized water on the day of analysis. Standards were
prepared in the concentration of 10, 7.5, 5, 2.5, and 1.25 µg/mL of heparin sulfate solution.
Samples were prepared by adding 10 µL of 0.1 mM platinum compounds to 200 µL of 10 µg/mL
in a test tube. The samples were allowed to react for 30 mins prior to the analysis. The samples
were prepared in duplicates.

UV-Visible Spectroscopy
Standards and the samples were measured by using HP (Agilent) 8453 UV/Vis spectroscopy. To
150 µL of the standards or samples, 150 µL of methylene blue was added and vortexed, then
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subsequently measured by UV-Vis spectroscopy. Full visible absorption spectrum (400-800 nm)
was measured for all of the standards and samples to determine the optimal wavelength for the
quantification.

Determination of Calibration Curve

Figure 5.26. Absorption spectra of standards. To 150 µL of heparin samples at various concentrations
(0 µg/mL to 10 µg/mL), 150 µL of MB solution was added, then measured immediately.

Figure 5.26 shows the absorption spectra MB and MB-heparin complexes from 400 nm to
800 nm. With increased heparin concentration in the mixture, the absorption maxima of MB at
650 nm and 595 nm decreased, while a new absorption (heparin-MB) peak at 525 nm increased.
Previous published methods on heparin detection utilized the absorbance at 525 nm to observe the
interaction of methylene blue and sulfated molecules, where a new absorption peak appears
(203,202); however, based on the full spectra generated by various concentrations of standards,
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measuring a decrease in absorbance peaks at 650 nm provided better linearity and higher
sensitivity than measuring the absorbance at 525 nm (Figure 5.26).

Figure 5.27. Calibration curve at 650 nm.

This was also confirmed with the absorption spectra obtained upon PPC-NC treatment
(Figure 5.28). Absorption intensity of the peaks at 525 nm did not change significantly while
absorption at 595 nm and 650 nm demonstrated higher sensitivity. Overall, 650 nm provided the
highest sensitivity with best linearity with R-squared value of 0.9977 (Figure 5.27) and this
wavelength was selected to study the interaction of heparin and PPC-NC.
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Figure 5.28. Full absorption spectra upon treatment with PPC-NC. 150 µL of 10 µg/mL of heparin
sulfate solution was treated with 2.4 µM of PPC-NC. To this mixture, 150 µL of MB solution was added
then subsequently measured by UV/Vis spectroscopy.

Figure 5.29. Absorbance intensity at 650 nm after treatment with platinum compounds. 150 µL of 10
µg/mL of heparin sulfate solution was treated with 2.4 µM of PPC-NC. To this mixture, 150 µL of MB
solution was added then subsequently measured by UV/Vis spectroscopy.
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As shown in
Figure 5.29, Tetraplatin NC inhibited MB-heparin interaction most effectively compared
to other platinum compounds examined. The inhibition of MB-sulfate interaction by platinum
compounds can be linearly correlated by charge of the PPC-NC, where an increase in charge and
number of platinum center resulted in less heparin-MB binding. Interestingly, AH44 (6+)
interacted with heparin more effectively than Diplatin NC (6+) and exhibited a similar heparin
binding profile with Triplatin NC. This result is in an agreement with PPC-NC binding with DNA,
where the binding profile of AH44 was similar to that of Triplatin NC. Based on these findings, it
is suggested that number of platinum center is more crucial than charge of the PPC-NC in terms
of binding with heparin.

5.3.4 Effects of Heparin in DNA-Pt Binding
Experimental
CD experiments were performed as reported in Section 5.1.2. As stock solutions used in this study,
1 mM of DNA solution, 100 µM of Triplatin NC solution, and 300 µg/mL of heparin sulfate
solution were prepared in 10 mM of NaClO4. Further dilutions were made with 10 mM of NaClO4
to achieve desired final concentrations. Incubation was done in 37° C to mimic physiological
conditions. Experiments were performed in triplicate to confirm the results.

Results and Discussion
The mechanism of the cytotoxicity exhibited by PPC-NC is the PPC-NC and DNA adduct
formation through noncovalent interactions, which will cause structural disturbance of DNA,
ultimately triggering apoptosis. Previous studies have suggested that the uptake mechanism of
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PPC-NC is mediated by HSPG, where it enters the cells through endocytosis.

To exhibit

cytotoxicity, an internalized PPC-NC has to be released from the heparin sulfate in order to interact
with DNA to cause a structural perturbation. To investigate this, PPC-NC was allowed to react
with heparin sulfate before and after incubation with DNA and this interaction was monitored by
CD.

Figure 5.30. Effects of Heparin Sulfate on DNA Binding. A) 100 µM of CT-DNA was incubated with 30
µg/mL heparin sulfate for 1 h. B) 100 µM of CT-DNA was incubated with 10 µM of Triplatin NC for 1 h. C)
10 µM of Triplatin NC was incubated with 60 µg/mL heparin sulfate for 1 h, then 100 µM of CT-DNA was
added and incubated for additional 1 h. D) 100 µM of CT-DNA was incubated with 10 µM of Triplatin NC for
1 h, then 60 µg/mL heparin sulfate was added and incubated for additional 1 h.

Interestingly, there were no observed conformational changes in CT-DNA when PPC-NC
was incubated with heparin prior to the interaction with CT-DNA (Figure 5.30 C). This interaction
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was followed for several days to observe the reversibility of Pt-heparin adduct; however, no
conformation change was observed even after 96 h. This may suggest that the Pt-heparin adduct
is not easily reversible or PPC-NC preferentially bind to heparin over CT-DNA. Another
experiment was performed to test this hypothesis, where PPC-NC was incubated with CT-DNA
for 1 h, followed by incubation with heparin for addition 1 h (Figure 5.30 D). Even in this case,
no CT-DNA conformation change was observed by CD indicating that Pt-DNA adduct has been
reversed. Based on this finding, PPC-NC preferentiality binds to heparin versus CT-DNA. Further
investigation is necessary to examine this phenomenon.

Figure 5.31. Effects of heparinase I on PPC NC and heparin adduct. A) 100 µM of CT-DNA B) 10 U/mL
of heparinase I C) 100 µM of CT-DNA was incubated with 10 µM of Triplatin NC for 1 h, then 60 µg/mL
heparin sulfate was added and incubated for additional 1 h. C) 60 µg/mL heparin sulfate was incubated
with 10 µM of Triplatin NC for 1 h, then 100 µM of CT-DNA was added and incubated for additional 1 h. D)
30 µg/mL heparin sulfate was incubated with 10 µM of Triplatin NC for 1 h, then 100 µM of CT-DNA was
added and incubated for additional 1 h. To the mixture, heparinase I was added and incubated for 0.5 h.

105

Based on the CD study of heparin and Triplatin NC, Triplatin NC preferentially binds to
heparin, whereas it needs to be released from the heparin to exhibit cytotoxic activity by interacting
with DNA. To explore a possible mechanism of its release from heparin, heparinase I was added
to the solution, where Pt-heparin adducts were present. Heparanase I is an enzyme known to cleave
hepaain and is essential for the release of polyamines (e.g. spermine, spermidine) after cellular
internalization mediated by heparan sulfate proteoglycans (HSPG) (192,204,205).
The CD spectrum of DNA shows a distinct positive band at 274 nm, whereas heparinase I
does not contribute any CD signal at this wavelength. When CT-DNA was treated with Triplatin
NC pre-incubated with heparin, no DNA conformation change was observed (Figure 5.31 C);
however, when heparinase I was added to the mixture, the positive band at 274 nm from CT-DNA
became a negative band, indicating a significant conformation changes of CT-DNA structure
(Figure 5.31 C). This may suggest that the mechanism of PPC-NC is similar to cell entry of
cationic polyamine mediate by HSPG, where PPC-NC binds to cell surface HSPG, uptake by
endocytosis, release upon heparan degradation through heparanase, then ultimately binding to
DNA. Although PPC-NC showed to inhibit the enzymatic activity of heparanase in previous study,
it is suggested from this result that heparanese may be responsible for the release of PPC-NC bound
to HSPG in the cells. Yet, one study is not enough to conclude the complex cellular entry
mechanism of PPN-NC, and further investigation are necessary to confirm these findings and to
fully understand the mechanism of cellular internalization of PPC-NC.
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5.4 Contributions
Cytotoxicity was done by Samantha Katner.
Daniel E. Lee and Samantha Katner contributed equally to cellular accumulation study.
All of other work reported in this chapter was done by Daniel E. Lee.
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Chapter 6

Other Contributions
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CHAPTER 6.

OTHER CONTRIBUTIONS

6.1 Hybrid Polynuclear Platinum Compounds
A major problem of BBR3464 was degradation of the compound into inactive metabolites,
where one of the fragments shown in blood metabolism studies was identified as Monoplatin NC
(206). This pharmacokinetic problem has discouraged to continue the investigation of BBR3464
in the clinical setting. A cell proliferation study with PPC-NC reported in section 5.2 shows that
Monoplatin NC did not exhibit significant cytotoxic activity in cells, while Di-, Tri-, and
Tetraplatin NC exhibited micromolar cytotoxic activity in cells. This gave a motivation to further
investigate the PPC-Cl, where one of the fragments of Tetraplatin-Cl and Pentaplatin-Cl formed
upon inactivation by sulfur molecules are cytotoxic Diplatin NC and Triplatin NC, respectively
(Figure 6.1).
Tetraplatin-Cl and Pentaplatin-Cl are predicted to exhibit two distinct modes of action: 1)
exhibits nanomolar cytotoxicity as seen with BBR3464 by covalently binding with DNA. 2) if they
are degraded by sulfur nucleophiles, they will release Diplatin NC and Triplatin NC to exhibit
micromolar cytotoxicity by interacting with DNA through noncovalent interactions. This novel
approach may trigger two distinct cell death mechanism by exhibiting different modes of DNA
binding and which may resolve the pharmacokinetic problems of BBR3464. To allow investigation
of this hypothesis, Tetraplatin-Cl(synthesized in Chapter 4) and Pentaplatin-Cl are synthesized,
characterized, and evaluated.
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Figure 6.1. Metabolites of PPC-Cl analogs produced upon metabolic degradation by sulfur
nucleophiles. Tri-, Tetra-, and Pentaplatin-Cl releases Mono-, Di-, and Triplatin NC, respectively.

110

6.1.1 Synthesis of Pentaplatin-Cl

Figure 6.2. Synthetic scheme of Pentaplatin-Cl

Syntheses and characterization of BBR3464 and Tetraplatin-Cl are described in Section 4.2.

Pentaplatin-Cl
To 1 mmol of Triplatin NC dissolved in DMF, 2.2 mmol of DIPEA was added while stirring. 2.2
mmol of mono-activated transplatin was added to the solution and the mixture was allow react for
2 days at ambient temperature. The solution was evaporated to dryness under reduced pressure
and was dissolved in minimum amount of water. The reaction was filtered through syringe filter
to remove any unreacted starting material. The filtrate was evaporated to ~1 mL under reduced
pressure and 25 mL of acetone was added to precipitate the product. The precipitant was collected
through filter and was washed with acetone.
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Pentaplatin-Cl- (Yield: 39%). 1H NMR (D2O): δ 2.7ppm (16H, m), 1.7(16H, m), 1.4 (16H, m).
Elemental Anal calc’d for C24H94Cl2N26O24Pt5- C 13.24, H 4.35, N 16.72. Obtained- C 13.33, H
4.38, N 16.68.

6.1.2 Active Metabolites of Novel PPC-Cl with Dual Antitumor Activity

Experimental Conditions
Electrospray ionization time of flight mass spectrometry
Platinum compounds were prepared at a final concentration of 3 mM and were incubated with Nacetyl-cysteine in a reaction ratio of 1:4 (platinum complex: N-acetyl-cysteine) in a mixture of
water and methanol (70: 30, v:v) for 16 h. pH was adjusted to 7.4 using NaOH. Experiments were
conducted on a Waters/Micromass QTOF-2 instrument operated in positive ion mode. An
electrospray voltage of 4.5kV and a capillary temperature of 200 ºC were used. The infusion rate
was 3 uL/min. Collision gas was introduced into the hexapole to aid in ion cooling. All spectra
were analyzed using the MassLynx 4.0 software provided from the manufacturer.

195Pt

NMR Spectroscopy

Platinum compounds were prepared at a final concentration of 3 mM and were incubated with Nacetyl-methionine in a reaction ratio of 1:4 (platinum complex: N-acetyl-cysteine) in H2O/D2O
(70:30, v.v) for 16 h. pH was adjusted to 7.4 by using NaOH.
Na2[PtCl6]. The scanning frequency for

195

195

Pt spectra were referenced to

Pt nuclei was set at 64.32 MHz. All spectra were

analyzed using Mestranova 8.1 software.
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Figure 6.3. Proposed structures of PPC-Cl.

Results and Discussion
The structures of the platinum compounds studied are shown in Figure 6.3. ESI-MS and
195

Pt NMR spectroscopy were utilized to confirm our hypothesis that PPC-NC will be released

upon the metabolic degradation of PPC-Cl. BBR3464, Tetraplatin, and Pentaplatin-Cl were
allowed to react with 4 equivalents of n-acetyl-cysteine at pH 7.4 for 16 hours to allow complete
degradation. N-acetyl-cysteine was specifically selected for this study since thiols are abundant in
a physiological environment (e.g. glutathione) and are known to rapidly degrade platinum
compounds into inactive metabolites.

Figure 6.4. Inactive metabolites produced by PPC upon the interaction with NAC.
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Figure 6.5. Reaction of PPC with NAC followed by ESI-MS. i. BBR3464 with NAC. ii. TetraplatinClwith NAC. iii. Pentaplatin-Cl with NAC. A. PPC-NC: Monoplatin NC(i), Diplatin NC(ii), and Triplatin
NC (iii). B. Inactive metabolite: [Pt(NH3)2(NAC)2]+. C. Thiolate bridged inactive metabolite [(NAC)(NH3)2PtNAC-Pt(NAC)(NH3)2]+. (The structures of B and C are shown in Figure 6.4).
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Upon the reaction of BBR3464 with NAC, Monoplatin NC (460.27 m/z, 1+) was observed
as one of its metabolites (Figure 6.5i). Sulfur bound inactive platinum metabolite B and sulfurbridged metabolite C were also observed at 554.07 m/z (1+) and 944.10 m/z (1+), respectively
(Figure 6.5). Similar products were seen with Tetraplatin-Cl and Pentaplatin-Cl, where they
produced Diplatin NC (268.47 m/z, 4+; 402.21 m/z, 3+) and Triplatin NC (287.39 m/z, 4+; 382.85
m/z), as well as inactive metabolite B and C (Figure 6.5ii-iii). The results from this study confirms
our hypothesis by producing PPC-NC compounds as one of their metabolites.

Figure 6.6. Reaction of PPC-Cl with NAC followed by 195Pt NMR spectroscopy. A. Tetraplatin-Cl, B.
Tetraplatin-Cl with NAC.
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To confirm this result, 195Pt NMR spectroscopy was also utilized to identify the metabolites
under the same condition (Figure 6.6). 195Pt NMR spectroscopy is a very useful tool to distinguish
different ligand substituents bound to the platinum compounds. Upon the reaction with NAC, PPCCl produced PPC-NC (PtN4) and their inactive metabolites (PtN2S2) as shown in Figure 6.6. By
utilizing these chemical techniques, the release of PPC-NC upon metabolic degradation of PPCCl was confirmed. These structurally novel compounds with active metabolites can be a solution
to the pharmacokinetic problems of BBR3464; furthermore, it can potentially reduce the
possibility of developing drug resistance by exhibiting two distinct mode of action. Further
investigation including biological assays are deserved to confirm that these compounds exhibit
dual antitumor activity in cells.

6.2 Synthesis of a Carboxylate Derivative of BBR3464
The utilization of carboxylate strategy was proven to enhance the pharmacological
properties of cisplatin by allowing slower substitution kinetics while it has also resulted in higher
cellular accumulation and increased water solubility (207,208,209). Utilizing more stable
carboxylate leaving group in place of chloride on TPA compounds also resulted in improved
pharmacological profiles including enhanced stability to sulfur nucleophiles (84,71,66). Phase II
clinical drug BBR3464 was discouraged due to rapid degradation into inactive metabolites. To
address the pharmacokinetics problems of BBR3464, a carboxylate derivative of BBR3464 was
synthesized as shown in Figure 6.7.
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Figure 6.7. Synthetic scheme of BBR3464-Acetate.

Synthetic Procedure of BBR3464-Acetate
The synthesis of BBR3464-acetate is adopted and modified from a method published
previously (210)
0.5 mmol of BBR3464 chloride salt was dissolved in 10 mL water. 3.0 mmol of silver acetate was
added and the mixture allowed to stir overnight in dark at 50°C. Next day, the solution was filtered
through membrane filters twice to remove silver chloride formed.

Then the solution was

evaporated to minimal volume (0.5 ~ 1 mL). Then 20 mL of acetone and ether were added and
stirred at 4°C to allow precipitation. The product was collected by filter and then was washed with
acetone. If further purification was necessary, the crude product was recrystallized from water.
1H

NMR: δ 2.65 (quin, 8H), 2.0 (s, 6H), 1.9 (s, 12H), 1.67 (m, 8H), 1.38(m, 8H). Elemental

Analysis: Expected - C, 22.62, H 5.38, N 10.99. Found- C 22.25, H 5.11, N 10.46.

trans configuration platinum compounds (e.g TPA) utilized weak trans influencing
carboxylates in trans position to another, which resulted in significantly enhanced stability than
its chloride analog, while cis configuration platinum compounds (oxaliplatin and carboplatin) have
utilized bidentate carboxylate to accomplish the enhanced stability. However, BBR3464 has the
leaving group trans axial to amine linker, which exerts greater trans influence than the
carboxylates, which may result in faster substitution kinetics. As a consequence, BBR3464-acetate
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did not significantly enhance the stability of the compound; therefore, further investigation of PPC
carboxylates was not made.
Although carboxylate strategy on BBR3464 did not result in enhanced stability, this
compound may be useful for other purpose. Our collaborator from University of British Columbia
(Center for Drug Research and Development) is currently investigating on liposomal formulation
of BBR3464, which is intended to protect the drug against metabolic inactivation, and to deliver
more drug more selectively to the site of tumor growth, thereby increasing efficacy and lowering
toxicity. BBR3464-acetate may enhance the association with the surface of liposomal nanoparticle,
where this will be further investigated by our collaborator.

6.3 Synthesis of TPA Succinate Compound.
The usage of cisplatin is limited due to its toxic side. The lack of specificity of conventional
cytotoxic platinum agents is a major clinical problem. Conventional antitumor agents have a
narrow therapeutics window and are distributed to normal and cancer cells in nonselective manner
(137). A key objective of this was to develop platinum based drugs with equal cytotoxicity but
reduced toxicity by enhancing its specificity to tumor tissue.
Tumor cell survival, growth, and metastasis are driven by angiogenesis, the process by which
new blood vessels are formed. Tumor blood vessels are morphologically distinct from normal
blood vessels and it has become a major target for treating cancer selectively (211,212). Among
the cell surface proteins upregulated in tumor cells during tumor growth and metastasis, αVβ3 and
αVβ5 integrin are attractive targets since they recognize a peptide motif containing RGD (Arg-GlyAsp) motifs (Figure 6.8) (213).
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Figure 6.8. Structure of RGD tripeptide

Figure 6.9. Structure of trans-Pt[(isq)(NH3)(succinate)2].

On the basis of these finding, we have attempted to conjugate RGD tripeptide to our TPA
compounds to enhance its specificity to target tumors. TPA compounds are suitable for this
purpose since it employs leaving carboxylate group trans axial to each other, which significantly
slows down the rate of hydrolysis due to low trans effect and influence exerted by the carboxylates.
To allow conjugation of RGD peptide to TPA compounds, the compound shown in Figure 6.9 was
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synthesized. This structure allows RGD coupling with terminal carboxylate groups of the succinate
moieties.

Synthetic Consideration
During the synthesis of succinate platinum compounds, platinum compounds may
polymerize since platinum can bind with either carboxyl moiety of succinic acid. Synthesis of
trans-[Pt(isq)(NH3)(succinate)2] was initially attempted by utilizing mono-methyl protected
succinate, followed by acid hydrolysis, to avoid polymerization of the platinum compound (Figure
6.10). However, this attempt was not successful since isoquinoline ligand and Pt-carboxylate bond
were more vulnerable to acid hydrolysis than methyl group on the carboxylate. In an alternate
approach, excess amount (20 equivalents) of succinic was added to trans- [Pt(isq)(NH3)(I)2]
activated with silver nitrate and this method successfully produced the desired product (Figure
6.11).

6.3.1 Attempt to synthesize the succinate TPA by utilizing methylated succinate
followed by acid hydrolysis

Figure 6.10. Attempt to synthesize trans-Pt[(isq)(NH3)(succinate)2] by using methylated succinate

trans-[Pt(isq)(NH3)(I)2]- Prepared as reported in section 2.2.
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Silver methyl succinate- 2 mmol of mono-methyl succinate was dissolved in 10 ml of water. 1.2
mmol of silver oxide was added and stirred in dark for 16 h. Excess silver oxide was removed by
filtering through 0.2µm syringe filter. The filtrate was lyophilized in dark and white powder was
collected. 1H NMR(D2O): δ 3.6(s, 3H), 2.7(m, 4H).

trans-[Pt(isq)(NH3)(mono-methyl succinate)2]- 1 mmol of trans-[Pt(isq)(NH3)I2] was suspended
in water. 1.98 eq. of silver methyl succinate dissolved in water was slowly added to the solution.
The reaction was allowed to stir overnight in dark. Next day, silver iodide formed during the
reaction was removed by filtering through celite. The filtrate was evaporated to dryness under
reduced pressure. The solid was suspended in acetone, filtered, and washed with methanol/acetone.
The product was characterized by 1H NMR spectroscopy and CHN elemental analysis. 1H NMR
(D2O): δ 9.6 (s, 1H), 8.7(d, 1H), 8.3(d, 1H), 8.1(d, 1H), 7.9(d, 1H), 7.6(m, 2H), 3.6(s, 6H), 2.7(m,
8H). Anal. Calc’d for C19H24N2O8Pt: C 37.81, H 4.01, N 4.64. Found: C 37.62, H 4.12, N 4.49.

Acid hydrolysis- Acid hydrolysis was attempted by using following acid at different
concentrations, temperature, and reaction time: Hydrochloric acid, nitric acid, trifluoroacetic acid,
phosphoric acid, and acetic acid. Based on 1H NMR spectroscopy, it was evident that isoquinoline
on TPA compound was more susceptible to acid than the methyl group on the succinate, where
the peak corresponds to isoquinoline has disappeared significantly faster than methyl group on
succinate. At this point, an alternate approach was investigated.
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6.3.2 Synthesis of TPA-succinato compounds by using excess succinic acid

Figure 6.11. Synthesis of trans-Pt[(isq)(NH3)(succinate)2] by using excess succinic acid.

trans-[Pt(isq)(NH3)(succinate)2]- To 0.5 mmol of trans-[Pt(isq)(NH3)I2] suspended in water, 1.0
mmol of silver nitrate was added. The mixture was stirred for overnight in dark at room
temperature. Silver iodide formed was filtered through celite and 10 mmol of succinic acid was
added to the filtrate. The mixture was stirred at room temperature for 3 days. The solution was
evaporated to dryness and was dissolved in minimum amount of warm methanol. The product was
precipitated with ether. Precipitated product collected through filtration and was washed with
acetone and ether to remove any residual succinic acid. 1H NMR ((D2O): δ 9.6 (s, 1H), 8.7(d, 1H),
8.3(d, 1H), 8.1(d, 1H), 7.9(d, 1H), 7.6(m, 2H), 2.6(s, 8H). Anal. Calc’d for C17H20N2O8Pt: C
35.48, H 3.50, N 4.87. Found: C 35.62, H 3.52, N 4.69.
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Figure 6.12. Conjugation of RGD peptide to TPA.

Next step of this research involves coupling amine group of glycine in RGD peptide to
carboxylate terminal end of succinate moiety, which will be prepared as reported by Lippard et al
(Figure 6.12) (214). Next step was not accomplished since the coupling chemistry and separation
techniques used in this method were not within our expertise. This work may be re-attempted in
future.

6.4 Conjugation of NBD-Fluorophore
Polynuclear platinum compounds (PPC) are a structurally discrete class of platinum
compound whose pharmacological properties significantly differ from those of cisplatin. The
mechanism of cellular internalization was not thoroughly studied, yet they have shown
significantly higher cellular accumulation than cisplatin, while demonstrating micromolar
cytotoxicity in tumor cells. The use of molecular imagining techniques, such as confocal
microscopy, is an important tool in understanding of the drug trafficking and intracellular
distribution. Previous utilization of NBD (7-nitro-2,1,3-benzoxadiazole) fluorophore was made by
conjugating to Triplatin NC and cisplatin to examine the effects of protein association on
intracellular localization by confocal microscopy (215). The advantage of the NBD fluorophore is
123

that the size of the fluorophore is relatively small compare to other commercially available
fluorophores and NBD derivatives of Triplatin NC and cisplatin did not have much influences on
the biological properties of the platinum compounds.
The conjugation of NBD fluorophore can be made by attaching to unbound amine of
hexamethylenediamine linker of PPC, where the structure of analogues are not significantly
different from the parent compounds as shown in Figure 6.15. To further understand the cellular
internalization of PPC, an attempt was made to synthesize a series of PPC-NBD analogues, where
the compounds differ in charge, length, and the number of platinum centers as shown in Figure
6.13.

Figure 6.13. Proposed Structures of PPC-NBD Compounds
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6.4.1 Preparation of 6-NBD

Figure 6.14. Preparation of 6-NBD ligand.

All of the chemicals including NBD-Cl and n-boc-1,6-hexanediamine were purchased from
common vendors.

Adopted synthetic procedures from (216).
N-(tert-Butoxycarbonyl)-N′-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)hexamethylediamine
A solution of 7-nitrobenzo-2-oxa-1,3-diazol-4-yl chloride (0.398 g, 2.0 mmol) in 3.0 mL of
methanol was added dropwise in 5 min., under a nitrogen atmosphere at room temperature, to a
stirred solution of the N-BOC-1,6-diaminohexane (2.0 mmol) and triethylamine (0.31 mL, 2.2
mmol) in 4.0 mL of the same solvent. The dark solution was stirred at room temperature with the
exclusion of light for 15-20 h. The mixture was diluted with water and extracted with CHCl3. The
organic phase was dried over MgSO4 and evaporated to dryness.

Preparation of N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)hexamethylendiamine hydrochloride
(6-NBD)
N-(tert-Butoxycarbonyl)-N′-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)hexamethylediamine(1.9 mmol)
was dissolved in 8.0 mL of ethyl acetate and treated with 1.9 mL of 3 M HCl. After being stirred
at 60 ºC for 3 h, the mixture was concentrated at reduced pressure and the residue was washed
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with chloroform, yielding pure final product. Yield (72%). 1H NMR (CD3OH): δ 8.5 (d, 1H), δ
6.33 (d, 1H), δ 3.4 (m, 2H), δ 2.7 (m, 2H), δ 1.6 (m, 2H), δ 1.45 (m, 2H), δ 1.3 (m, 4H).

6.4.2 Attempt to Conjugate 6-NBD to PPC

Figure 6.15. General Scheme of NBD-Conjugation

Synthesis of 6-NBD was initially attempted by a synthetic method described by Chen et al
(217), where they react 1,6-hexanediamine with NBD-Cl. Greatest challenge with this method was
the formation of side product (bis-NBD-hexanediamine), where silica gel chromatography was
required to remove the side product formed during the reaction. This method was performed in
large volume of solvent and cold temperature (0 C°) to minimize the formation of side product;
however, the formation of the side product was inevitable with this approach. Thus, further
purification was necessary to obtain the desired product, whereas this method was very time
consuming with low yields of the products.
Different approach reported by Taliani et al was investigated, where mono-n-boc-1,6hexanediamine was conjugated to NBD-Cl followed by boc-deprotection. This method dispenses
the formation of the bis-NBD product (Figure 6.14) and allowed cleaner, faster, and more efficient
synthesis of 6-NBD. This method was utilized throughout this section to obtain 6-NBD required
for further syntheses.
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Conjugation of 6-NBD was attempted by following the synthetic procedure of PPC-NC,
where “dangling amine” was conjugated to PPC-Cl (Section 4.3). The starting materials
(transplatin, 1,1/t,t, BBR3464) were synthesized by synthetic procedures reported in Section 4.2.
The general synthetic schematic of NBD-derivative is shown in Figure 6.15, where the platinum
compounds were activated by adding 2 equivalents of silver nitrate, then 2.2 equivalents of
deprotonated 6-NBD ligand was added to accomplish the desired product.
The initial conjugation of 6-NBD was attempted on transplatin, which is the simplest
compound in the series; however, pure product was not obtained. Many purification methods were
attempted to purify the final product; washing with various organic solvents (acetone, acetonitrile,
and ether), recrystallization (methanol/dichloromethane), soxhlet extraction (dichloromethane),
and liquid-liquid extraction (water/dichloromethane). None of these purification steps allowed the
isolation of the pure product. This synthesis was also attempted on 1,1/t,t to synthesize DiplatinNBD; however, pure product was also not obtained.
Figure 6.16 (bottom) shows the most promising batch of Monoplatin-NBD obtained. A shift
of a peak from 2.4 ppm (protons of CH2-NH2) to 2.7 ppm (CH2-NH2-Pt) shows the occurrence of
the conjugation; however, there was a discrepancy of a peak integration at 3.5 ppm (CH2-NHNBD), where this reduced integration was found. The cause of this occurrence is not known and
this was also seen with NMR spectrum of Diplatin-NBD. CHN elemental analysis was obtained
to further characterize the compound, whereas obtained CHN values were significantly different
from theoretical CHN values, indicating that the obtained product was not pure. (MonoplatinNBD: Anal. Calc’d for C24H40N14O12P- C, 31.62; H, 4.42; N, 21.51. Found – C, 36.07; H, 3.92;
N, 20.87, Diplatin-NBD: Anal. Calc’d for C30H62N20O18Pt2- C, 26.09; H, 4.53; N, 20.28. Found
C, 36.71; H, 3.90; N, 19.19). Although NBD would be a useful tool to obtain details of cellular
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internalization and trafficking of the PPC, further attempts to conjugate NBD were not made due
to difficulties of the syntheses.

Figure 6.16. 1H NMR spectra of 6-NBD ligand (Top) and Monoplatin-NBD (Bottom). Due to difference
in solubility, 1H NMR spectrum of 6-NBD was obtained in CD3OH while the spectrum of Monoplatin-NBD
was obtained in D2O.
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6.5 Synthesis of Fluorine-18 Labelled Cisplatin
Positron Emission Tomography (PET) is a non-invasive quantitative medical imaging
technique that takes advantage of positron decay to offer in vivo imaging of labelled compound or
biomolecules (218,219). This technique allows one to obtain quantitative 2D and 3D biochemical
and physiological information through the use of positive emitting radioelements such as 11C, 13N,
15

O, and 18F (220). Development of a new imaging probe is rapidly expanding since it provide a

wealth of information for drug development and mechanism investigation including data on target
engagement, as well as pharmacokinetic and pharmacodynamic properties of the drug (221).
The most predominate isotope for radiolabeling of biomolecules for PET imaging is
Fluorine-18 (18F) because of its positron emitting property and favorable half-life of 109.8 min.
This half-life is significantly longer than 11C, 13N, and 15O, which allows enough time prepare the
labelled complex with even those involving multiple steps. The conversion of an alcohol to a
sulfonate ester (mesylate, tosylate, triflate) and reacting with 18F ion is a commonly used method
for fluorine-18 labelling (222).
Cisplatin is a chemotherapeutic agent commonly used in the treatment of a wide variety of
malignant tumors. DNA is known to be an important cellular target of cisplatin in living cells but
much of the cellular and molecular biology of cisplatin action still remains unknown. Many
attempts were made to obtain a cellular imaging of cisplatin by labelling the compounds with
fluorophores; however, they do not provide in vivo imaging capacity and they may not represent
cisplatin accurately due to relatively large structures of the fluorophores. To study the trafficking
and localization of cisplatin distribution in living animals by in vivo PET imaging, an attempt were
made to synthesize

18

F labelled cisplatin.

18

F labelling and PET imaging will be done with our

collaborator, Dr. Zweit (VCU molecular imaging center) with expertise in molecular imaging.

129

Figure 6.17. Proposed synthetic scheme of fluorine-18 labelled cisplatin

Intermediate cis-Pt[Cl2(butanolamine)(NH3)] was obtained by using synthetic approach
described in Figure 6.17; however, tosyl- or triflic- compounds were unable to be isolated due to
high reactivity of the compounds. Further attempts are suggested in a glove box, where inert
atmosphere is provided.

Experimental
Cisplatin was synthesized by using a method published previously (108).

Synthesis of K[PtCl3(NH3)] (TCAP)
Cisplatin (1g) was suspended in water (20 ml) and concentrated HCl (10 ml) was added. The
mixture was heated under reflux for 8 hours. The clear, orange colored solution was allowed to
cool to room temperature overnight. The mixture was filtered to remove any remaining cisplatin.
The filtrate was then reduced to approximately 5 mL under vacuum and stored in the refrigerator
overnight. Any precipitant (cisplatin) was filtered off. The ammonium salts (NH4[PtCl3(NH3)] and
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NH4[PtCl4]) were converted to potassium salts using a strong acidic cation exchanger. The
exchanger was converted into K+ form by rinsing with a 2 molar KCl solution. The column was
subsequently washed with water and the combined eluents were evaporated to dryness. If further
purification was necessary, the product was recrystallized in water/methanol (4:1).
.
Synthesis of cis-Pt[(Cl)(I)(butanolamine)(NH3)
The synthesis of this compound was achieved by a modification of a published procedure (223).
K[PtCl3(NH3)] (0.84 mmol) was dissolved in 2 ml of a 15 mM aqueous solution of KCl. KI (1.92
mmol) was added to the K[PtCl3(NH3)] solution, followed by the butanolamine (0.9 mmol). A
yellow precipitate was formed subsequently upon adding and the reaction was allowed to react for
30 minutes to allow the reaction to complete. Formed precipitant was collected, washed with cold
water, cold methanol and ether, and then dried under vacuum overnight.
(Yield 35%). 1H NMR (CD3COCD3): δ 4.4(t,2H), 3.5(t, 2H), 1.8(q, 2H), 1.5(q, 2H)

Synthesis of cis-Pt[Cl2(butanolamine)(NH3)
Cis-[PtICl(butanolamine)(NH3)] (0.2 mmol) was suspended in 5 ml of H2O and 1.6 equivalents of
silver nitrate was added to the suspension. It was then stirred overnight in the dark at room
temperature. Formed AgCl was filtered through celite and 0.5 ml of HCl (˜12 M) was added to the
filtrate. The solution was stirred at room temperature for 45 min and evaporated to dryness. The
light yellow precipitate suspended with methanol and collected through filter.
(Yield: 83%).

1

H NMR(D2O): δ 4.5(t,2H), 3.5(t, 2H), 1.8(q, 2H), 1.5(q, 2H) . Elemental Anal

calc’d for C4H14Cl2N2OPt- C 12.91, H 3.79, N 7.53. Found: C13.15, H 3.59, N 7.31.
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6.6 Platinum Recovery
Platinum is an expensive material and they are recovered from the laboratory wastes to reproduce
K2PtCl4, a substance used as a starting material in the synthesis of anticancer drugs.

Figure 6.18. Recovery of K2PtCl4 from platinum waste.

Preparation of Pt(0)
Excess NaOH was added to the liquid waste containing platinum until pH was higher than 10.
Then the solvent was evaporated under heat. The dried platinum was combined with solid waste
containing platinum, then they were heated to redness with Meker burner until fuming stops. The
ash was washed with warm water until the filtrate was clear. (Color of final product: black)
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Preparation of Hexachloroplatinic(IV) Acid [H2PtCl6] Solution
Aqua regia was prepared freshly by mixing concentrated nitric acid and hydrochloric acid in a
volume ratio of 1:3. Pure platinum metal was dissolved in gently heated aqua regia (30 mL per 1
g of platinum solid). The solution was cooled to the ambient temperature then filtered through
filter paper to remove any impurity. To precipitate K2PtCl6, KCl was added (1g ash: 1g KCl) to
the solution. A bright yellow precipitate of K2PtCl6 formed almost instantaneously and continued
throughout the addition of KCl. The solvent was reduced to 1/3 of the original volume by heating
then it was cooled in fridge to allow more precipitation. The precipitants were collected by filter
then washed with acetone and ether.

Preparation of Potassium Tetrachloroplatinate(II) [K2PtCl4]
K2PtCl6 was suspended in 0.1 M HCl (40g / 400mL) and heated to 65 °C. 0.5 equivalents of
hydrazine dihydrochloride dissolved in water was added dropwise to K2PtCl6 suspension over 2
hours. Then the mixture was allowed to react for additional 2 hours at 65° C. After 4 hours, only
a very small portion of solid K2PtCl6 remained in a very red solution. The platinum solution was
filtered while hot to remove the unreacted K2PtCl6. Then the filtrate was concentrated by heating
and any yellow precipitants were filtered out. This procedure was repeated until no yellow
precipitant was observed. The volume of the solution was reduced close to dryness then then
cooled in the fridge to force precipitation of K2PtCl4. The resultant red crystalline K2PtCl4 was
filtered then washed with acetone and allowed to air dry in a 50 °C oven.

Total Recovery: 90 g of K2PtCl4
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6.7 Contributions
All of the work in this chapter was done by Daniel E. Lee except for platinum recovery, where
Samantha Tsotsoros contributed equally.
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